WO2002044321A3 - Rna interference mediating small rna molecules - Google Patents

Rna interference mediating small rna molecules Download PDF

Info

Publication number
WO2002044321A3
WO2002044321A3 PCT/EP2001/013968 EP0113968W WO0244321A3 WO 2002044321 A3 WO2002044321 A3 WO 2002044321A3 EP 0113968 W EP0113968 W EP 0113968W WO 0244321 A3 WO0244321 A3 WO 0244321A3
Authority
WO
WIPO (PCT)
Prior art keywords
rna
dsrna
rnai
sequence
target rna
Prior art date
Application number
PCT/EP2001/013968
Other languages
French (fr)
Other versions
WO2002044321A2 (en
Inventor
Thomas Tuschl
Sayda Elbashir
Winfried Lendeckel
Matthias Wilm
Original Assignee
Max Planck Gesellschaft
Thomas Tuschl
Sayda Elbashir
Winfried Lendeckel
Matthias Wilm
Europ Lab Molekularbiolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40529293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002044321(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2001/010188 external-priority patent/WO2001075164A2/en
Application filed by Max Planck Gesellschaft, Thomas Tuschl, Sayda Elbashir, Winfried Lendeckel, Matthias Wilm, Europ Lab Molekularbiolog filed Critical Max Planck Gesellschaft
Priority to DE60130583.3T priority Critical patent/DE60130583T3/en
Priority to MXPA03004836A priority patent/MXPA03004836A/en
Priority to PL384789A priority patent/PL218881B1/en
Priority to PL365784A priority patent/PL218876B1/en
Priority to DK01985833.1T priority patent/DK1407044T4/en
Priority to HU0302557A priority patent/HU230458B1/en
Priority to EP01985833.1A priority patent/EP1407044B2/en
Priority to ES01985833.1T priority patent/ES2215494T5/en
Priority to KR1020037006978A priority patent/KR100872437B1/en
Priority to KR1020087011582A priority patent/KR100909681B1/en
Priority to BRPI0115814A priority patent/BRPI0115814B8/en
Priority to SI200130787T priority patent/SI1407044T2/en
Priority to IL15599101A priority patent/IL155991A0/en
Priority to AU2002235744A priority patent/AU2002235744B8/en
Priority to JP2002546670A priority patent/JP4095895B2/en
Priority to US10/433,050 priority patent/US20040259247A1/en
Priority to EP10179947.6A priority patent/EP2351852B2/en
Priority to EP17160119.8A priority patent/EP3199631B1/en
Priority to NZ525888A priority patent/NZ525888A/en
Priority to CA2429814A priority patent/CA2429814C/en
Publication of WO2002044321A2 publication Critical patent/WO2002044321A2/en
Priority to IL155991A priority patent/IL155991A/en
Priority to ZA200303929A priority patent/ZA200303929B/en
Priority to NO20032464A priority patent/NO333713B1/en
Publication of WO2002044321A3 publication Critical patent/WO2002044321A3/en
Priority to US10/832,248 priority patent/US7078196B2/en
Priority to US11/142,865 priority patent/US20050234006A1/en
Priority to US11/142,866 priority patent/US20050234007A1/en
Priority to US11/634,138 priority patent/US20080269147A1/en
Priority to US11/634,129 priority patent/US20070093445A1/en
Priority to AU2007203385A priority patent/AU2007203385B2/en
Priority to US12/260,443 priority patent/US20090155174A1/en
Priority to US12/537,602 priority patent/US8372968B2/en
Priority to US12/537,632 priority patent/US20100010207A1/en
Priority to US12/591,829 priority patent/US8853384B2/en
Priority to US12/683,070 priority patent/US8933044B2/en
Priority to US12/683,081 priority patent/US8362231B2/en
Priority to US12/794,071 priority patent/US8765930B2/en
Priority to US12/819,444 priority patent/US8796016B2/en
Priority to US12/834,311 priority patent/US8445237B2/en
Priority to US12/835,086 priority patent/US8778902B2/en
Priority to US12/838,786 priority patent/US8329463B2/en
Priority to IL207727A priority patent/IL207727A/en
Priority to US12/879,300 priority patent/US8993745B2/en
Priority to US12/897,374 priority patent/US8895718B2/en
Priority to US13/725,262 priority patent/US8895721B2/en
Priority to NO20130246A priority patent/NO335426B1/en
Priority to US14/476,465 priority patent/US9567582B2/en
Priority to US15/388,681 priority patent/US10633656B2/en
Priority to US16/805,072 priority patent/US20200299693A1/en
Priority to LTPA2021005C priority patent/LTPA2021005I1/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Abstract

Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3' ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
PCT/EP2001/013968 2000-12-01 2001-11-29 Rna interference mediating small rna molecules WO2002044321A2 (en)

Priority Applications (49)

Application Number Priority Date Filing Date Title
DE60130583.3T DE60130583T3 (en) 2000-12-01 2001-11-29 SMALL RNA MOLECULES TRANSFERRING RNA INTERFERENCE
MXPA03004836A MXPA03004836A (en) 2000-12-01 2001-11-29 Rna interference mediating small rna molecules.
PL384789A PL218881B1 (en) 2000-12-01 2001-11-29 Isolated double-strand RNA molecule and method for obtaining thereof, method for performing site-specific nucleic acid modifications, the use of method thereof, pharmaceutical agent, cell or organism, the use of cell of organism and the system for identification and/or characterization of pharmacological agent
PL365784A PL218876B1 (en) 2000-12-01 2001-11-29 Rna interference mediating small rna molecules
DK01985833.1T DK1407044T4 (en) 2000-12-01 2001-11-29 RNA interference mediating small RNA molecules
HU0302557A HU230458B1 (en) 2000-12-01 2001-11-29 Rna interference mediating small rna molecules
EP01985833.1A EP1407044B2 (en) 2000-12-01 2001-11-29 Rna interference mediating small rna molecules
ES01985833.1T ES2215494T5 (en) 2000-12-01 2001-11-29 Small RNA molecules that mediate RNA interference
KR1020037006978A KR100872437B1 (en) 2000-12-01 2001-11-29 RNA interference mediating small RNA molecules
KR1020087011582A KR100909681B1 (en) 2000-12-01 2001-11-29 RNA interference mediating small RNA molecules
BRPI0115814A BRPI0115814B8 (en) 2000-12-01 2001-11-29 double-stranded RNA molecules, their method of preparation and pharmaceutical composition comprising them
SI200130787T SI1407044T2 (en) 2000-12-01 2001-11-29 Rna interference mediating small rna molecules
IL15599101A IL155991A0 (en) 2000-12-01 2001-11-29 Rna interference mediating small rna molecules
AU2002235744A AU2002235744B8 (en) 2000-12-01 2001-11-29 RNA interference mediating small RNA molecules
JP2002546670A JP4095895B2 (en) 2000-12-01 2001-11-29 Short RNA molecules that mediate RNA interference
US10/433,050 US20040259247A1 (en) 2000-12-01 2001-11-29 Rna interference mediating small rna molecules
EP10179947.6A EP2351852B2 (en) 2000-12-01 2001-11-29 RNA interference mediating small RNA molecules
EP17160119.8A EP3199631B1 (en) 2000-12-01 2001-11-29 Rna interference mediating small rna molecules
NZ525888A NZ525888A (en) 2000-12-01 2001-11-29 RNA interference mediating small RNA molecules
CA2429814A CA2429814C (en) 2000-12-01 2001-11-29 Rna interference mediating small rna molecules
IL155991A IL155991A (en) 2000-12-01 2003-05-19 Rna interference mediating small rna molecules
ZA200303929A ZA200303929B (en) 2000-12-01 2003-05-21 RNA interference mediating small RNA molecules.
NO20032464A NO333713B1 (en) 2000-12-01 2003-05-30 Isolated, double-stranded RNA molecule and its use, process for its preparation, in vitro method for mediating template-specific RNA interferences and its use, as well as pharmaceutical composition
US10/832,248 US7078196B2 (en) 2000-12-01 2004-04-27 RNA interference mediating small RNA molecules
US11/142,865 US20050234006A1 (en) 2000-12-01 2005-06-02 RNA interference mediating small RNA molecules
US11/142,866 US20050234007A1 (en) 2000-12-01 2005-06-02 RNA interference mediating small RNA molecules
US11/634,138 US20080269147A1 (en) 2000-12-01 2006-12-06 RNA interference mediating small RNA molecules
US11/634,129 US20070093445A1 (en) 2000-12-01 2006-12-06 RNA interference mediating small RNA molecules
AU2007203385A AU2007203385B2 (en) 2000-12-01 2007-07-19 RNA interference mediating small RNA molecules
US12/260,443 US20090155174A1 (en) 2000-12-01 2008-10-29 RNA Interference Mediating Small RNA Molecules
US12/537,602 US8372968B2 (en) 2000-12-01 2009-08-07 RNA interference mediating small RNA molecules
US12/537,632 US20100010207A1 (en) 2000-12-01 2009-08-07 Rna interference mediating small rna molecules
US12/591,829 US8853384B2 (en) 2000-12-01 2009-12-02 RNA interference mediating small RNA molecules
US12/683,070 US8933044B2 (en) 2000-12-01 2010-01-06 RNA interference mediating small RNA molecules
US12/683,081 US8362231B2 (en) 2000-12-01 2010-01-06 RNA interference mediating small RNA molecules
US12/794,071 US8765930B2 (en) 2000-12-01 2010-06-04 RNA interference mediating small RNA molecules
US12/819,444 US8796016B2 (en) 2000-12-01 2010-06-21 RNA interference mediating small RNA molecules
US12/834,311 US8445237B2 (en) 2000-12-01 2010-07-12 RNA interference mediating small RNA molecules
US12/835,086 US8778902B2 (en) 2000-12-01 2010-07-13 RNA interference mediating small RNA molecules
US12/838,786 US8329463B2 (en) 2000-12-01 2010-07-19 RNA interference mediating small RNA molecules
IL207727A IL207727A (en) 2000-12-01 2010-08-19 Rna interference mediating small rna molecules
US12/879,300 US8993745B2 (en) 2000-12-01 2010-09-10 RNA interference mediating small RNA molecules
US12/897,374 US8895718B2 (en) 2000-12-01 2010-10-04 RNA interference mediating small RNA molecules
US13/725,262 US8895721B2 (en) 2000-12-01 2012-12-21 RNA interference mediating small RNA molecules
NO20130246A NO335426B1 (en) 2000-12-01 2013-02-14 Isolated double stranded RNA molecule for use in medicine
US14/476,465 US9567582B2 (en) 2000-12-01 2014-09-03 RNA interference mediating small RNA molecules
US15/388,681 US10633656B2 (en) 2000-12-01 2016-12-22 RNA interference mediating small RNA molecules
US16/805,072 US20200299693A1 (en) 2000-12-01 2020-02-28 Rna interference mediating small rna molecules
LTPA2021005C LTPA2021005I1 (en) 2000-12-01 2021-05-18

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP00126325.0 2000-12-01
EP00126325 2000-12-01
US27966101P 2001-03-30 2001-03-30
PCT/US2001/010188 WO2001075164A2 (en) 2000-03-30 2001-03-30 Rna sequence-specific mediators of rna interference
USPCT/US01/10188 2001-03-30
US60/279,661 2001-03-30

Related Child Applications (15)

Application Number Title Priority Date Filing Date
US10/433,050 A-371-Of-International US20040259247A1 (en) 2000-12-01 2001-11-29 Rna interference mediating small rna molecules
US10433050 A-371-Of-International 2001-11-29
US10/832,432 Division US7056704B2 (en) 2000-12-01 2004-04-27 RNA interference mediating small RNA molecules
US10/832,248 Division US7078196B2 (en) 2000-12-01 2004-04-27 RNA interference mediating small RNA molecules
US10/832,257 Division US20050026278A1 (en) 2000-12-01 2004-04-27 RNA interference mediating small RNA molecules
US11/142,866 Division US20050234007A1 (en) 2000-12-01 2005-06-02 RNA interference mediating small RNA molecules
US11/142,865 Division US20050234006A1 (en) 2000-12-01 2005-06-02 RNA interference mediating small RNA molecules
US11/634,138 Division US20080269147A1 (en) 2000-12-01 2006-12-06 RNA interference mediating small RNA molecules
US11/634,129 Division US20070093445A1 (en) 2000-12-01 2006-12-06 RNA interference mediating small RNA molecules
US12/260,443 Division US20090155174A1 (en) 2000-12-01 2008-10-29 RNA Interference Mediating Small RNA Molecules
US12/537,632 Division US20100010207A1 (en) 2000-12-01 2009-08-07 Rna interference mediating small rna molecules
US12/537,602 Division US8372968B2 (en) 2000-12-01 2009-08-07 RNA interference mediating small RNA molecules
US12/683,070 Division US8933044B2 (en) 2000-12-01 2010-01-06 RNA interference mediating small RNA molecules
US12/683,081 Division US8362231B2 (en) 2000-12-01 2010-01-06 RNA interference mediating small RNA molecules
US12/897,374 Continuation US8895718B2 (en) 2000-12-01 2010-10-04 RNA interference mediating small RNA molecules

Publications (2)

Publication Number Publication Date
WO2002044321A2 WO2002044321A2 (en) 2002-06-06
WO2002044321A3 true WO2002044321A3 (en) 2003-10-23

Family

ID=40529293

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/013968 WO2002044321A2 (en) 2000-12-01 2001-11-29 Rna interference mediating small rna molecules

Country Status (28)

Country Link
US (25) US20040259247A1 (en)
EP (3) EP2348133B1 (en)
JP (5) JP4095895B2 (en)
KR (2) KR100909681B1 (en)
CN (1) CN100523215C (en)
AT (1) ATE373724T2 (en)
AU (3) AU2002235744B8 (en)
BR (1) BRPI0115814B8 (en)
CA (1) CA2429814C (en)
CY (1) CY1119062T1 (en)
CZ (2) CZ308053B6 (en)
DE (1) DE60130583T3 (en)
DK (2) DK2813582T3 (en)
ES (2) ES2728168T3 (en)
HK (4) HK1110631A1 (en)
HU (1) HU230458B1 (en)
IL (3) IL155991A0 (en)
LT (1) LTPA2021005I1 (en)
MX (1) MXPA03004836A (en)
NO (2) NO333713B1 (en)
NZ (1) NZ525888A (en)
PL (1) PL218876B1 (en)
PT (1) PT1407044E (en)
RU (2) RU2322500C2 (en)
SI (1) SI1407044T2 (en)
TR (1) TR200401292T3 (en)
WO (1) WO2002044321A2 (en)
ZA (1) ZA200303929B (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655232B2 (en) 2002-12-24 2010-02-02 Pfizer Inc. Anti-NGF antibodies and methods using same
US7888325B2 (en) 1999-01-28 2011-02-15 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US8846894B2 (en) 2002-02-20 2014-09-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8895266B2 (en) 2000-10-06 2014-11-25 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell
US8946177B2 (en) 2004-11-12 2015-02-03 Mima Therapeutics, Inc Methods and compositions involving miRNA and miRNA inhibitor molecules
US8999947B2 (en) 2005-06-14 2015-04-07 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US9051566B2 (en) 2001-01-31 2015-06-09 Alnylam Pharmaceuticals, Inc. Post-transcriptional gene silencing using expressed double stranded RNA
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9279009B2 (en) 2007-12-03 2016-03-08 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services FILIP1L nucleic acid fragments
US9376690B2 (en) 2009-10-30 2016-06-28 Northwestern University Templated nanoconjugates
US9506056B2 (en) 2006-06-08 2016-11-29 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US9592250B2 (en) 2002-02-01 2017-03-14 Life Technologies Corporation Double-stranded oligonucleotides

Families Citing this family (1184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023569A1 (en) * 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US5639647A (en) * 1994-03-29 1997-06-17 Ribozyme Pharmaceuticals, Inc. 2'-deoxy-2'alkylnucleotide containing nucleic acid
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20040219569A1 (en) * 1999-07-06 2004-11-04 Fruma Yehiely Gene identification method
WO2006094406A1 (en) * 2005-03-11 2006-09-14 Sarissa Inc. Antisense oligonucleotides targeted to the coding region of thymidylate synthase and uses thereof
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP1071762A4 (en) 1998-03-20 2003-09-24 Benitec Australia Ltd Control of gene expression
EP1071753A2 (en) * 1998-04-20 2001-01-31 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
US7601494B2 (en) 1999-03-17 2009-10-13 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6656698B1 (en) * 1999-06-30 2003-12-02 Millennium Pharmaceuticals, Inc. 12832, a novel human kinase-like molecule and uses thereof
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
GB9925459D0 (en) * 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
DE10100586C1 (en) 2001-01-09 2002-04-11 Ribopharma Ag Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
DE10160151A1 (en) * 2001-01-09 2003-06-26 Ribopharma Ag Inhibiting expression of target gene, useful e.g. for inhibiting oncogenes, by administering double-stranded RNA complementary to the target and having an overhang
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7179796B2 (en) * 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20050032733A1 (en) * 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US20080039414A1 (en) * 2002-02-20 2008-02-14 Sima Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
IL151781A0 (en) 2000-03-16 2003-04-10 Genetica Inc Methods and compositions for rna interference
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
EP2345742B1 (en) * 2000-03-30 2014-06-11 The Whitehead Institute for Biomedical Research RNA sequence-specific mediators of RNA interference
BRPI0117338B1 (en) * 2000-03-30 2016-06-21 Massachusetts Inst Technology method for producing knockout animal cells in vitro and method for producing knockout animal cells
US7662791B2 (en) 2000-08-02 2010-02-16 University Of Southern California Gene silencing using mRNA-cDNA hybrids
US20080242627A1 (en) * 2000-08-02 2008-10-02 University Of Southern California Novel rna interference methods using dna-rna duplex constructs
CA2417214C (en) * 2000-08-03 2016-06-21 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
US20030190635A1 (en) * 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
US20080032942A1 (en) 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20020165192A1 (en) * 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
US7691821B2 (en) * 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
CZ308053B6 (en) 2000-12-01 2019-11-27 Max Planck Gesellschaft Isolated double-stranded RNA molecule, process for producing it and its use
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
WO2003070750A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc Rna interference mediated inhibition of hepatitis c virus
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US20050176024A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA)
US20050176666A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
US20050196781A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA)
US20050159379A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
US20040019001A1 (en) * 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20050176663A1 (en) * 2001-05-18 2005-08-11 Sima Therapeutics, Inc. RNA interference mediated inhibition of protein tyrosine phosphatase type IVA (PRL3) gene expression using short interfering nucleic acid (siNA)
US20050239731A1 (en) * 2001-05-18 2005-10-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20050119212A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US20080161256A1 (en) * 2001-05-18 2008-07-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050054596A1 (en) * 2001-11-30 2005-03-10 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050209180A1 (en) * 2001-05-18 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20050048529A1 (en) * 2002-02-20 2005-03-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20090299045A1 (en) * 2001-05-18 2009-12-03 Sirna Therapeutics, Inc. RNA Interference Mediated Inhibition Of Interleukin and Interleukin Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20080188430A1 (en) * 2001-05-18 2008-08-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20050164967A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) * 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
WO2005014811A2 (en) * 2003-08-08 2005-02-17 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF XIAP GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2526831C (en) * 2001-05-18 2012-07-31 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US20050176664A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
US20050137155A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050164224A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050191618A1 (en) * 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
US20050256068A1 (en) * 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20050187174A1 (en) * 2001-05-18 2005-08-25 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20050267058A1 (en) * 2001-05-18 2005-12-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
US20050182007A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20050124569A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050222066A1 (en) * 2001-05-18 2005-10-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050164968A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US20050233996A1 (en) * 2002-02-20 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20060142225A1 (en) * 2001-05-18 2006-06-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
US20060148743A1 (en) * 2001-05-18 2006-07-06 Vasant Jadhav RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)
US20050287128A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050158735A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
US20050261219A1 (en) * 2001-05-18 2005-11-24 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US20050136436A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
US20050159381A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
US20070270579A1 (en) * 2001-05-18 2007-11-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20070093437A1 (en) * 2001-05-18 2007-04-26 Sirna Therapeutics, Inc. Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina)
US20050079610A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050233344A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
US20060211642A1 (en) * 2001-05-18 2006-09-21 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050159378A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US20040219671A1 (en) * 2002-02-20 2004-11-04 Sirna Therapeutics, Inc. RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)
US20050159380A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050153914A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
EP1390472A4 (en) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
US8008472B2 (en) 2001-05-29 2011-08-30 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
CA2451643C (en) 2001-06-21 2012-11-13 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
EP2345720A3 (en) 2001-07-12 2012-01-25 University of Massachusetts In vivo production of small interfering RNAs that mediate gene silencing
DE10133858A1 (en) * 2001-07-12 2003-02-06 Aventis Pharma Gmbh Synthetic double-stranded oligonucleotides for targeted inhibition of gene expression
CA2936534C (en) 2001-07-23 2021-01-26 The Board Of Trustees Of Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
US10590418B2 (en) * 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
US20090247606A1 (en) * 2001-08-28 2009-10-01 Sirna Therapeutics, Inc. RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20030198627A1 (en) * 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
DE10163098B4 (en) 2001-10-12 2005-06-02 Alnylam Europe Ag Method for inhibiting the replication of viruses
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
CN1604783A (en) * 2001-10-26 2005-04-06 里伯药品公司 Drug for treating a fibrotic disease through rna interfence
DE10230996A1 (en) * 2001-10-26 2003-07-17 Ribopharma Ag Method for inhibiting viral replication, useful particularly for treating hepatitis C infection, by altering the 3'-untranslated region of the virus
CN1608133A (en) * 2001-10-26 2005-04-20 里伯药品公司 Use of a double-stranded ribonucleic acid for treating an infection with a positivestrand rna-virus
WO2003035870A1 (en) * 2001-10-26 2003-05-01 Ribopharma Ag Drug for treating a carcinoma of the pancreas
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
EP1448586A4 (en) * 2001-11-02 2006-03-01 Intradigm Corp Therapeutic methods for nucleic acid delivery vehicles
AU2002368202B2 (en) * 2001-11-02 2008-06-05 Insert Therapeutics, Inc Methods and compositions for therapeutic use of RNA interference
KR100990055B1 (en) * 2001-11-21 2010-10-26 사이고 가오루 Method of inhibiting gene expression
US20070203333A1 (en) * 2001-11-30 2007-08-30 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040138163A1 (en) * 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050075304A1 (en) * 2001-11-30 2005-04-07 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
AU2003237616B2 (en) 2002-01-17 2007-07-05 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
DE10202419A1 (en) 2002-01-22 2003-08-07 Ribopharma Ag Method of inhibiting expression of a target gene resulting from chromosome aberration
GB0201477D0 (en) * 2002-01-23 2002-03-13 Novartis Forschungsstiftung Methods of obtaining isoform specific expression in mammalian cells
EP1572902B1 (en) * 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
JP2005515780A (en) 2002-02-01 2005-06-02 セクイター インコーポレイテッド Double stranded oligonucleotide
US20050096289A1 (en) * 2002-02-07 2005-05-05 Hans Prydz Methods and compositions for modulating tissue factor
IL163547A0 (en) * 2002-02-12 2005-12-18 Quark Biotech Inc Use of the axl receptor for diagnosis and treatment of renal disease
AU2003214363A1 (en) * 2002-02-13 2003-09-04 Axordia Limited Method to modify differentiation of pluripotential stem cells
WO2003068797A1 (en) 2002-02-14 2003-08-21 City Of Hope Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules
US8258288B2 (en) 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US7897753B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20090233983A1 (en) * 2002-02-20 2009-09-17 Sirna Therapeutics Inc. RNA Interference Mediated Inhibition of Protein Tyrosine Phosphatase-1B (PTP-1B) Gene Expression Using Short Interfering RNA
JP2005517423A (en) * 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド RNA interference-mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acids (siNA)
US8013143B2 (en) 2002-02-20 2011-09-06 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
US7928218B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20090253773A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1495041A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA INTERFERENCE MEDIATED INHIBITION OF G72 AND D-AMINO ACID OXIDASE (DAAO) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2003213005A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN KINASE C ALPHA (PKC-ALPHA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7897757B2 (en) 2002-02-20 2011-03-01 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US20090099117A1 (en) 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003106476A1 (en) * 2002-02-20 2003-12-24 Sirna Therapeutics, Inc Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
EP1501853A4 (en) * 2002-02-20 2005-11-16 Sirna Therapeutics Inc RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US7935812B2 (en) 2002-02-20 2011-05-03 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US7928220B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
US7667030B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20090247613A1 (en) * 2002-02-20 2009-10-01 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20090253774A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7928219B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
US7893248B2 (en) 2002-02-20 2011-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US7910724B2 (en) 2002-02-20 2011-03-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US20090137509A1 (en) * 2002-02-20 2009-05-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATION CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7667029B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20050096284A1 (en) * 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US8232383B2 (en) * 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7662952B2 (en) 2002-02-20 2010-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
JP2005517433A (en) * 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド RNA interference-mediated inhibition of TNF and TNF receptor superfamily gene expression using short interfering nucleic acids (siNA)
US7691999B2 (en) 2002-02-20 2010-04-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
US7678897B2 (en) 2002-02-20 2010-03-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US20090093439A1 (en) * 2002-02-20 2009-04-09 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7683165B2 (en) * 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US7683166B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US20090192105A1 (en) 2002-02-20 2009-07-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
US20090306182A1 (en) * 2002-02-20 2009-12-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MAP KINASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7897752B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
US7795422B2 (en) 2002-02-20 2010-09-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20100240730A1 (en) * 2002-02-20 2010-09-23 Merck Sharp And Dohme Corp. RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA)
JP2005517450A (en) * 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド RNA interference-mediated target discovery and target evaluation using short interfering nucleic acids (siNA)
US7700760B2 (en) 2002-02-20 2010-04-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US8067575B2 (en) 2002-02-20 2011-11-29 Merck, Sharp & Dohme Corp. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
WO2003072745A2 (en) * 2002-02-22 2003-09-04 Eshleman James R Antigene locks and therapeutic uses thereof
EP2277522B1 (en) * 2002-03-01 2012-11-21 UCB Manufacturing, Inc. Methods for increasing or decreasing bone density and identifying molecules
AU2003228301A1 (en) * 2002-03-06 2003-09-22 Rigel Pharmaceuticals, Inc. Novel method for delivery and intracellular synthesis of sirna molecules
US7274703B2 (en) * 2002-03-11 2007-09-25 3Com Corporation Stackable network units with resiliency facility
EP1495141A4 (en) * 2002-03-20 2006-03-22 Massachusetts Inst Technology Hiv therapeutic
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
EP1495121A2 (en) * 2002-04-18 2005-01-12 Lynkeus Biotech GmbH Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US8137910B2 (en) 2002-05-03 2012-03-20 Duke University Method of regulating gene expression
WO2003099227A2 (en) 2002-05-23 2003-12-04 Ceptyr, Inc. Modulation of ptp1b signal transduction by rna interference
US7199107B2 (en) * 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
AU2003237686A1 (en) * 2002-05-24 2003-12-12 Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Rna interference mediating small rna molecules
US20100075423A1 (en) * 2002-06-12 2010-03-25 Life Technologies Corporation Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
GB2406169B (en) * 2002-06-12 2006-11-01 Ambion Inc Methods and compositions relating to labeled rna molecules that reduce gene expression
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
US20030235916A1 (en) * 2002-06-14 2003-12-25 Monahan Sean D. Novel methods for the delivery of polynucleotides to cells
EP1539951A1 (en) * 2002-06-21 2005-06-15 Sinogenomax Co., Ltd. Randomised dna libraries and double-stranded rna libraries, use and method of production thereof
JP2005537028A (en) * 2002-06-26 2005-12-08 ザ　ペン　ステート　リサーチ　ファウンデーション Methods and materials for treating human papillomavirus infections
JP4722481B2 (en) 2002-06-28 2011-07-13 プロティバ バイオセラピューティクス リミテッド Liposome production method and apparatus
EP2333062A1 (en) 2002-07-10 2011-06-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA-interference by single-stranded RNA molecules
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
AU2012216354B2 (en) * 2002-08-05 2016-01-14 Silence Therapeutics Gmbh Further novel forms of interfering RNA molecules
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
DE60310944T3 (en) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh OTHER NEW FORMS OF INTERFERING RNS MOLECULES
EP1389637B1 (en) 2002-08-05 2012-05-30 Silence Therapeutics Aktiengesellschaft Blunt-ended interfering RNA molecules
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
AU2015264957B2 (en) * 2002-08-05 2017-10-26 Silence Therapeutics Gmbh Further novel forms of interfering rna molecules
SI1527176T1 (en) * 2002-08-05 2007-06-30 Silence Terapeutics Ag Further novel forms of interfering rna molecules
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
ES2378987T3 (en) * 2002-08-06 2012-04-19 Toray Industries, Inc. Remedy or preventive agent for kidney disease and procedure to diagnose kidney disease
CN1720257A (en) * 2002-08-06 2006-01-11 因特拉迪格姆公司 Methods of down regulating target gene expression in vivo by introduction of interfering RNA
AU2003261449A1 (en) 2002-08-07 2004-02-25 Compositions for rna interference and methods of use thereof
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
KR101295939B1 (en) * 2002-08-14 2013-09-09 사일런스 테라퓨틱스 아게 Use of protein kinase ｎ beta
AU2003258426B2 (en) 2002-08-21 2008-04-10 The University Of British Columbia RNAi probes targeting cancer-related proteins
US7956176B2 (en) * 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
US20060287269A1 (en) * 2002-09-09 2006-12-21 The Regents Of The University Of California Short interfering nucleic acid hybrids and methods thereof
US20040138119A1 (en) * 2002-09-18 2004-07-15 Ingo Tamm Use of hepatitis B X-interacting protein (HBXIP) in modulation of apoptosis
WO2004027063A1 (en) * 2002-09-19 2004-04-01 Institut National De La Sante Et De La Recherche Medicale-Inserm Use of sirnas for gene silencing in antigen presenting cells
CA2500224C (en) 2002-09-25 2015-04-28 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
AU2003279004B2 (en) * 2002-09-28 2009-10-08 Massachusetts Institute Of Technology Influenza therapeutic
US20060240425A1 (en) * 2002-09-30 2006-10-26 Oncotherapy Science, Inc Genes and polypeptides relating to myeloid leukemia
US7422853B1 (en) * 2002-10-04 2008-09-09 Myriad Genetics, Inc. RNA interference using a universal target
AU2003291678B2 (en) * 2002-11-01 2009-01-15 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
US7892793B2 (en) 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
AU2003291682A1 (en) * 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
EP1578765A4 (en) 2002-11-05 2008-04-23 Isis Pharmaceuticals Inc Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
DE10322662A1 (en) * 2002-11-06 2004-10-07 Grünenthal GmbH New DNA type 10-23 enzyme, useful for treating e.g. pain, and related short interfering RNA, directed against the vanillin receptor or picorna viruses, contains specific nucleotide modifications for improved stability
US20090227780A1 (en) * 2002-11-14 2009-09-10 Dharmacon, Inc. siRNA targeting connexin 43
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7592442B2 (en) * 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US7655785B1 (en) 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20100113307A1 (en) * 2002-11-14 2010-05-06 Dharmacon, Inc. siRNA targeting vascular endothelial growth factor (VEGF)
US7691998B2 (en) * 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US20090005548A1 (en) * 2002-11-14 2009-01-01 Dharmacon, Inc. siRNA targeting nuclear receptor interacting protein 1 (NRIP1)
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US8163896B1 (en) 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US20080268457A1 (en) * 2002-11-14 2008-10-30 Dharmacon, Inc. siRNA targeting forkhead box P3 (FOXP3)
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US10920226B2 (en) * 2002-11-14 2021-02-16 Thermo Fisher Scientific Inc. siRNA targeting LDHA
JP2006507841A (en) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド Functional and ultrafunctional siRNA
US7927793B2 (en) 2002-11-18 2011-04-19 The United States Of America As Represented By The Department Of Health And Human Services Cell lines and host nucleic acid sequences related to infectious disease
US7064337B2 (en) 2002-11-19 2006-06-20 The Regents Of The University Of California Radiation detection system for portable gamma-ray spectroscopy
DE10254214A1 (en) * 2002-11-20 2004-06-09 Beiersdorf Ag Oligoribonucleotides for the treatment of degenerative skin symptoms by RNA interference
AU2003298718A1 (en) * 2002-11-22 2004-06-18 University Of Massachusetts Modulation of hiv replication by rna interference
CN101914532A (en) * 2002-11-22 2010-12-15 生物智囊团株式会社 Method of detecting target base sequence of rna interference
JP4526228B2 (en) * 2002-11-22 2010-08-18 隆 森田 Novel therapeutic methods and therapeutic agents using RNAi
US7618948B2 (en) * 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
EP1585756B1 (en) * 2002-11-26 2010-04-21 University of Massachusetts Delivery of sirnas
US20130130231A1 (en) 2002-11-26 2013-05-23 Isaac Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
US7696334B1 (en) 2002-12-05 2010-04-13 Rosetta Genomics, Ltd. Bioinformatically detectable human herpesvirus 5 regulatory gene
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
CN1301263C (en) 2002-12-18 2007-02-21 北京昭衍新药研究中心 Nucleotide sequence for anti HIV infection and preventing AIDS and use thereof
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US20070141009A1 (en) * 2003-01-03 2007-06-21 Shaharyar Khan Sirna mediated post-transriptional gene silencing of genes involved in alopecia
ATE477337T1 (en) 2003-01-16 2010-08-15 Univ Pennsylvania COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ICAM-1
US7629323B2 (en) * 2003-01-21 2009-12-08 Northwestern University Manipulation of neuronal ion channels
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
US20060178297A1 (en) * 2003-01-28 2006-08-10 Troy Carol M Systems and methods for silencing expression of a gene in a cell and uses thereof
US7732591B2 (en) 2003-11-25 2010-06-08 Medtronic, Inc. Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
AU2004211949A1 (en) * 2003-02-05 2004-08-26 University Of Massachusetts RNAi targeting of viruses
FR2850971B1 (en) * 2003-02-10 2006-08-11 Aventis Pharma Sa ANTISENSE OLIGONUCLEOTIDE INHIBITING OB-RGRP PROTEIN EXPRESSION AND METHOD OF DETECTING COMPOUNDS THAT MODIFY THE INTERACTION BETWEEN THE OB-RGRP PROTEIN FAMILY AND THE LEPTIN RECEPTOR
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
US20040162235A1 (en) * 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
BRPI0407375A (en) 2003-02-19 2006-02-07 Rinat Neuroscience Corp Methods for treating pain by administering a neural growth factor antagonist and a nsaid and compositions containing same
US8796235B2 (en) * 2003-02-21 2014-08-05 University Of South Florida Methods for attenuating dengue virus infection
CA2516425A1 (en) * 2003-02-21 2005-02-24 The Penn State Research Foundation Rna interference compositions and methods
CN1780913A (en) * 2003-02-27 2006-05-31 独立行政法人产业技术总合研究所 Induction of methylation of CpG sequences by dsRNA in mammalian cells
AU2004214954A1 (en) * 2003-02-27 2004-09-10 Alnylam Pharmaceuticals, Inc. Methods and constructs for evaluation of RNAi targets and effector molecules
CA2517974A1 (en) * 2003-03-05 2004-09-16 Senesco Technologies, Inc. Use of antisense oligonucleotides or sirna to suppress expression of eif-5a1
US20050164212A1 (en) * 2003-03-06 2005-07-28 Todd Hauser Modulation of gene expression using DNA-RNA hybrids
AU2004220556B2 (en) 2003-03-07 2009-05-07 Alnylam Pharmaceuticals, Inc. Therapeutic compositions
US7862816B2 (en) * 2003-03-12 2011-01-04 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
DK1606406T4 (en) 2003-03-21 2013-12-16 Santaris Pharma As Short Interfering RNA (siRNA) Analogues
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
WO2004090105A2 (en) * 2003-04-02 2004-10-21 Dharmacon, Inc. Modified polynucleotides for use in rna interference
ATE536408T1 (en) * 2003-04-02 2011-12-15 Dharmacon Inc MODIFIED POLYNUCLEOTIDES FOR USE IN RNA INTERFERENCE
EP1631669A2 (en) 2003-04-09 2006-03-08 Biodelivery Sciences International, Inc. Cochleate compositions directed against expression of proteins
AU2004229519B2 (en) 2003-04-09 2011-07-21 Alnylam Pharmaceuticals, Inc. iRNA conjugates
US20070270360A1 (en) * 2003-04-15 2007-11-22 Sirna Therapeutics, Inc. Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
EP2664672A1 (en) 2003-04-17 2013-11-20 Alnylam Pharmaceuticals Inc. Modified iRNA agents
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US8796436B2 (en) 2003-04-17 2014-08-05 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
EP1625138A4 (en) 2003-04-17 2010-06-23 Alnylam Pharmaceuticals Inc Protected monomers
JP2006523464A (en) * 2003-04-18 2006-10-19 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア Compositions and methods for siRNA inhibition of angiopoietins 1, 2 and their receptor TIE2
WO2005032595A2 (en) * 2003-04-23 2005-04-14 Georgetown University Methods and compositions for the inhibition of stat5 in prostate cancer cells
EP1644048B1 (en) * 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US7619068B2 (en) 2003-05-09 2009-11-17 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US7524653B2 (en) 2003-05-09 2009-04-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small interfering RNA libraries and methods of synthesis and use
AU2003241409A1 (en) * 2003-05-12 2005-01-21 Potomac Pharmaceuticals, Inc. Gene expression suppression agents
WO2004104199A2 (en) * 2003-05-15 2004-12-02 Oligo Engine, Inc. Modulation of gene expression using dna-dna hybrids
US8609830B2 (en) * 2003-05-16 2013-12-17 Merck Sharp & Dohme Corp. Methods and compositions for RNA interference
US20070243570A1 (en) 2003-05-19 2007-10-18 Genecare Research Institute Co., Ltd Apoptosis Inducer for Cancer Cell
EP1637144A4 (en) * 2003-05-30 2010-01-13 Nippon Shinyaku Co Ltd Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite
EP2251039A3 (en) 2003-05-30 2010-12-08 Nippon Shinyaku Co., Ltd. Oligo double-stranded rna inhibiting the expression of bcl-2 and pharmaceutical composition containing the same
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
EP1633767B1 (en) * 2003-06-02 2018-11-21 University of Massachusetts Methods and compositions for controlling efficacy of rna silencing
WO2005001043A2 (en) * 2003-06-02 2005-01-06 University Of Massachusetts METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi
WO2005002507A2 (en) * 2003-06-03 2005-01-13 Isis Pharmaceuticals, Inc. Modulation of survivin expression
US20050019918A1 (en) * 2003-06-03 2005-01-27 Hidetoshi Sumimoto Treatment of cancer by inhibiting BRAF expression
US7595306B2 (en) * 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
DK3604537T3 (en) * 2003-06-13 2022-02-28 Alnylam Europe Ag Double-stranded ribonucleic acid with increased efficiency in an organism
EP1486564A1 (en) * 2003-06-13 2004-12-15 Ribopharma AG SiRNA with increased stability in serum
WO2005044976A2 (en) * 2003-06-20 2005-05-19 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
WO2004113496A2 (en) * 2003-06-20 2004-12-29 Isis Pharmaceuticals, Inc. Double stranded compositions comprising a 3’-endo modified strand for use in gene modulation
EP2371835A1 (en) * 2003-07-03 2011-10-05 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
EP1649019A2 (en) * 2003-07-15 2006-04-26 California Institute Of Technology Improved inhibitor nucleic acids
US20050256071A1 (en) * 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
AU2004257373B2 (en) * 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US20050079614A1 (en) * 2003-07-21 2005-04-14 Reinhart Brenda J. RNAs able to modulate chromatin silencing
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7888497B2 (en) 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
CA2535516A1 (en) * 2003-08-13 2005-03-03 The Board Of Trustees Of The University Of Illinois Silencing of tgf-beta receptor type ii expression by sirna
US7825235B2 (en) * 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
WO2005035759A2 (en) * 2003-08-20 2005-04-21 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HYPOXIA INDUCIBLE FACTOR 1 (HIF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050136437A1 (en) * 2003-08-25 2005-06-23 Nastech Pharmaceutical Company Inc. Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
US20070203084A1 (en) 2003-08-28 2007-08-30 Jan Weiler Interfering Rna Duplex Having Blunt-Ends And 3'-Modifications
US8501705B2 (en) * 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
ES2808561T3 (en) * 2003-09-12 2021-03-01 Univ Massachusetts RNA interference for the treatment of gain-of-function disorders
EP2182063A3 (en) * 2003-09-18 2012-07-18 Isis Pharmaceuticals, Inc. Modulation of EIF4E expression
EP1670955A2 (en) * 2003-09-22 2006-06-21 Rosetta Inpharmatics LLC. Synthetic lethal screen using rna interference
WO2005033310A1 (en) * 2003-10-01 2005-04-14 Grünenthal GmbH Pim-1 specific dsrna compounds
US20080249038A1 (en) * 2003-10-07 2008-10-09 Quark Biotech, Inc. Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof
EP1711613B1 (en) 2003-10-09 2013-04-10 E.I. Du Pont De Nemours And Company Gene silencing by using micro-rna molecules
WO2005045032A2 (en) * 2003-10-20 2005-05-19 Sima Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2543029A1 (en) * 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gpra and aaa1 gene expression using short nucleic acid (sina)
CA2542835A1 (en) * 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
AU2004286261B2 (en) 2003-10-27 2010-06-24 Merck Sharp & Dohme Llc Method of designing siRNAs for gene silencing
US8227434B1 (en) 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
US20070275918A1 (en) * 2003-11-07 2007-11-29 The Board Of Trustees Of The University Of Illinois Induction of Cellular Senescence by Cdk4 Disruption for Tumor Suppression and Regression
EP1697515A4 (en) * 2003-11-12 2008-02-06 Austin Research Inst Dna-carrier conjugate
JP2005168485A (en) * 2003-11-20 2005-06-30 Tsutomu Suzuki METHOD FOR DESIGNING siRNA
US7763592B1 (en) * 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7807646B1 (en) * 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US20050208658A1 (en) * 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
US20100145038A1 (en) * 2003-11-24 2010-06-10 Merck & Co., Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2005053725A2 (en) * 2003-11-26 2005-06-16 The Queen's University Of Belfast Cancer treatment
GB2424887B (en) 2003-11-26 2008-05-21 Univ Massachusetts Sequence-specific inhibition of small RNA function
US20070238676A1 (en) * 2003-12-04 2007-10-11 Mohapatra Shyam S Polynucleotides for Reducing Respiratory Syncytial Virus Gene Expression
JP2007513968A (en) * 2003-12-12 2007-05-31 ウイスコンシン アラムニ リサーチ ファンデーション Delivery of siRNA to mammalian neurons
JPWO2005068630A1 (en) * 2003-12-16 2007-07-26 独立行政法人産業技術総合研究所 Double-stranded RNA for interference
US20060134787A1 (en) * 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
JP2007515966A (en) * 2003-12-23 2007-06-21 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア Compositions and methods for combined therapy of diseases
US20070161586A1 (en) * 2004-01-16 2007-07-12 Takeda Pharmaceutical Company Limited Drug for preventing and treating atherosclerosis
DE602005025347D1 (en) 2004-01-30 2011-01-27 Quark Pharmaceuticals Inc OLIGORIBONUCLEOTIDES AND METHODS FOR THEIR USE IN THE TREATMENT OF FIBROTIC SUDDEN AND OTHER DISEASES
WO2005073378A1 (en) * 2004-01-30 2005-08-11 Santaris Pharma A/S MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA)
WO2005078094A2 (en) * 2004-02-06 2005-08-25 Dharmacon, Inc. Stabilized rnas as transfection controls and silencing reagents
CA2554212A1 (en) * 2004-02-10 2005-08-25 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina)
US20060019914A1 (en) 2004-02-11 2006-01-26 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
WO2005079533A2 (en) * 2004-02-17 2005-09-01 University Of Massachusetts Methods and compositions for mediating gene silencing
WO2005079532A2 (en) * 2004-02-17 2005-09-01 University Of Massachusetts Methods and compositions for enhancing risc activity in vitro and in vivo
EP1566202A1 (en) * 2004-02-23 2005-08-24 Sahltech I Göteborg AB Use of resistin antagonists in the treatment of rheumatoid arthritis
JP2007523214A (en) * 2004-02-23 2007-08-16 ジェンザイム コーポレイション Method for enhancing MUC1 antagonist of death receptor ligand-induced apoptosis
AU2005226779B8 (en) 2004-02-24 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rab9A, Rab11A, and modulators thereof related to infectious disease
US7691823B2 (en) * 2004-03-05 2010-04-06 University Of Massachusetts RIP140 regulation of glucose transport
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US20050202075A1 (en) * 2004-03-12 2005-09-15 Pardridge William M. Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
EP1735009A4 (en) 2004-03-12 2011-03-30 Alnylam Pharmaceuticals Inc iRNA AGENTS TARGETING VEGF
US20070265220A1 (en) * 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
EP2514758B2 (en) 2004-03-15 2021-06-23 City of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
US20050272682A1 (en) * 2004-03-22 2005-12-08 Evers Bernard M SiRNA targeting PI3K signal transduction pathway and siRNA-based therapy
US7851452B2 (en) * 2004-03-22 2010-12-14 The Trustees Of The University Of Pennsylvania Methods of use of bcl-6-derived nucleotides to induce apoptosis
WO2005095622A2 (en) * 2004-03-26 2005-10-13 Van Andel Research Institute c-met siRNA ADENOVIRUS VECTORS INHIBIT CANCER CELL GROWTH, INVASION AND TUMORIGENICITY
CA2561221C (en) * 2004-03-26 2016-09-20 Curis, Inc. Rna interference modulators of hedgehog signaling and uses thereof
JPWO2005095647A1 (en) * 2004-03-31 2008-02-21 タカラバイオ株式会社 siRNA screening method
JP2005312428A (en) * 2004-03-31 2005-11-10 Keio Gijuku Treatment of cancer by utilizing skp-2 expression inhibition
KR101147147B1 (en) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Modified polynucleotides for reducing off-target effects in rna interference
WO2005097817A2 (en) 2004-04-05 2005-10-20 Alnylam Pharmaceuticals, Inc. Process and reagents for oligonucleotide synthesis and purification
JP4761389B2 (en) 2004-04-09 2011-08-31 株式会社ジーンケア研究所 Cancer cell-specific apoptosis inducer targeting genes related to chromosome stabilization
US20060078902A1 (en) * 2004-04-15 2006-04-13 Michaeline Bunting Method and compositions for RNA interference
CA2564616C (en) * 2004-04-20 2016-08-30 Nastech Pharmaceutical Company Inc. Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
CA2557532A1 (en) 2004-04-23 2005-11-10 Angela M. Christiano Inhibition of hairless protein mrna
CA2562685C (en) * 2004-04-27 2013-09-17 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
EP1744761A4 (en) 2004-04-28 2010-01-13 Molecules For Health Inc Methods for treating or preventing restenosis and other vascular proliferative disorders
US7674778B2 (en) 2004-04-30 2010-03-09 Alnylam Pharmaceuticals Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
US20110117088A1 (en) * 2004-05-12 2011-05-19 Simon Michael R Composition and method for introduction of rna interference sequences into targeted cells and tissues
US20050260214A1 (en) * 2004-05-12 2005-11-24 Simon Michael R Composition and method for introduction of RNA interference sequences into targeted cells and tissues
US20060030003A1 (en) * 2004-05-12 2006-02-09 Simon Michael R Composition and method for introduction of RNA interference sequences into targeted cells and tissues
WO2005111211A2 (en) 2004-05-14 2005-11-24 Rosetta Genomics Ltd. Micronas and uses thereof
US7687616B1 (en) 2004-05-14 2010-03-30 Rosetta Genomics Ltd Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
WO2005110464A2 (en) * 2004-05-14 2005-11-24 Oregon Health & Science University Irx5 inhibition as treatment for hyperproliferative disorders
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
AU2005287383B2 (en) * 2004-05-25 2011-09-22 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
EP2471922A1 (en) * 2004-05-28 2012-07-04 Asuragen, Inc. Methods and compositions involving microRNA
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
EP1781593B1 (en) * 2004-06-07 2011-12-14 Protiva Biotherapeutics Inc. Cationic lipids and methods of use
JP4796062B2 (en) 2004-06-07 2011-10-19 プロチバ バイオセラピューティクス インコーポレイティッド Lipid-encapsulating interfering RNA
US20060008907A1 (en) * 2004-06-09 2006-01-12 The Curators Of The University Of Missouri Control of gene expression via light activated RNA interference
WO2006085942A2 (en) * 2004-06-17 2006-08-17 The Regents Of The University Of California Compositions and methods for regulating gene transcription
US20060051815A1 (en) * 2004-06-25 2006-03-09 The J. David Gladstone Institutes Methods of treating smooth muscle cell disorders
EP1789553B1 (en) 2004-06-30 2014-03-26 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a non-phosphate backbone linkage
EP1773857A4 (en) * 2004-07-02 2009-05-13 Protiva Biotherapeutics Inc Immunostimulatory sirna molecules and uses therefor
EP1765378B1 (en) 2004-07-12 2014-04-16 Medical Research Fund of Tel Aviv Sourasky Medical Center Agent capable of downregulating an msf-a-dependent hif-1a and use thereof in cancer treatment
AU2005330703A1 (en) * 2004-07-19 2006-10-26 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
US20060030538A1 (en) * 2004-07-21 2006-02-09 Medtronic, Inc. Methods for reducing or preventing localized fibrosis using SiRNA
WO2006093526A2 (en) 2004-07-21 2006-09-08 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
WO2006020231A2 (en) * 2004-07-21 2006-02-23 Medtronic, Inc. Medical devices and methods for reducing localized fibrosis
EP2484780A1 (en) 2004-07-23 2012-08-08 The University of North Carolina At Chapel Hill Methods and materials for determining pain sensibility and predicting and treating related disorders
AU2005330637B2 (en) 2004-08-04 2012-09-20 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
EP2990410A1 (en) 2004-08-10 2016-03-02 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
WO2006020557A2 (en) * 2004-08-10 2006-02-23 Immusol, Inc. Methods of using or identifying agents that inhibit cancer growth
EP1789592A4 (en) * 2004-08-13 2009-12-23 Univ Delaware Method for identification and quantification of short or small rna molecules
AP2007003921A0 (en) 2004-08-16 2007-02-28 Atugen Ag Therapeutic uses of inhibitors of rtp801
SI1781787T1 (en) * 2004-08-23 2017-08-31 Sylentis S.A.U. Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas
US20070021366A1 (en) * 2004-11-19 2007-01-25 Srivastava Satish K Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
WO2006026738A2 (en) 2004-08-31 2006-03-09 Qiagen North American Holdings, Inc. Methods and compositions for rna amplification and detection using an rna-dependent rna-polymerase
AU2005278918B2 (en) * 2004-08-31 2010-07-29 Sylentis S.A.U. Methods and compositions to inhibit P2X7 receptor expression
US7884086B2 (en) * 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
JP2008512500A (en) 2004-09-10 2008-04-24 ソマジェニックス インコーポレーティッド Small interfering RNA that efficiently inhibits viral gene expression and method of use thereof
FI20041204A0 (en) 2004-09-16 2004-09-16 Riikka Lund Methods for the utilization of new target genes associated with immune-mediated diseases
WO2006033965A2 (en) * 2004-09-16 2006-03-30 The Trustees Of The University Of Pennsylvania Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
CN101133074B (en) * 2004-09-24 2012-05-30 阿尔尼拉姆医药品有限公司 RNAi modulation of APOB and uses thereof
ES2594083T3 (en) 2004-09-28 2016-12-15 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of their use for the treatment of alopecia, acute renal failure and other diseases
EP1796686A4 (en) * 2004-09-30 2008-05-14 Centocor Inc Emmprin antagonists and uses thereof
KR20070085421A (en) 2004-10-21 2007-08-27 벤간자 아이엔씨 Methods and materials for conferring resistance to pests and pathogens of plants
US7943755B2 (en) * 2004-10-22 2011-05-17 Neuregenix Limited Neuron regeneration
US20060110440A1 (en) * 2004-10-22 2006-05-25 Kiminobu Sugaya Method and system for biasing cellular development
US7592322B2 (en) * 2004-10-22 2009-09-22 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US7790878B2 (en) * 2004-10-22 2010-09-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
WO2006047687A2 (en) * 2004-10-27 2006-05-04 Schering Corporation Compositions and methods for short interfering nucleic acid inhibition of nav1.8
SG156690A1 (en) 2004-10-27 2009-11-26 Univ Vanderbilt Mammalian genes involved in infection
AU2005302554A1 (en) * 2004-10-28 2006-05-11 Idexx Laboratories, Inc. Compositions for controlled delivery of pharmaceutically active compounds
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2008073922A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
US20060105052A1 (en) * 2004-11-15 2006-05-18 Acar Havva Y Cationic nanoparticle having an inorganic core
US8809287B2 (en) * 2004-11-15 2014-08-19 Icahn School Of Medicine At Mount Sinai Compositions and methods for altering Wnt autocrine signaling
US20060134189A1 (en) * 2004-11-17 2006-06-22 Protiva Biotherapeutics, Inc siRNA silencing of apolipoprotein B
PT2189469E (en) * 2004-11-18 2016-01-22 Univ Illinois Multicistronic sirna constructs to inhibit tumors
WO2006054625A1 (en) * 2004-11-19 2006-05-26 Genecare Research Institute Co., Ltd. Cancer-cell-specific cytostatic agent
US7923206B2 (en) * 2004-11-22 2011-04-12 Dharmacon, Inc. Method of determining a cellular response to a biological agent
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
US7935811B2 (en) 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
AU2005323303A1 (en) * 2004-11-24 2006-07-13 Alnylam Pharmaceuticals, Inc. RNAi modulation of the Bcr-Abl fusion gene and uses thereof
US20060160110A1 (en) * 2004-12-02 2006-07-20 Takayuki Mizutani Methods of designing small interfering RNAs, antisense polynucleotides, and other hybridizing polynucleotides
US20060165667A1 (en) * 2004-12-03 2006-07-27 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
JP2008523157A (en) * 2004-12-14 2008-07-03 アルナイラム ファーマシューティカルズ インコーポレイテッド RNAi regulation of MLL-AF4 and methods of use thereof
JP5601756B2 (en) 2004-12-17 2014-10-08 ベス イスラエル デアコネス メディカル センター， インコーポレイテッド Compositions for bacteria-mediated gene silencing and methods of use thereof
GB0427916D0 (en) * 2004-12-21 2005-01-19 Astrazeneca Ab Method
US20060142228A1 (en) 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
TWI386225B (en) 2004-12-23 2013-02-21 Alcon Inc Rnai inhibition of ctgf for treatment of ocular disorders
EP1830888B1 (en) 2004-12-27 2015-08-05 Silence Therapeutics GmbH Lipid complexes coated with peg and their use
BRPI0519690A2 (en) * 2004-12-30 2009-03-03 Todd M Hauser compositions and methods for modulating gene expression using self-protected oligonucleotides
AU2005322960A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
NZ556097A (en) * 2005-01-07 2009-12-24 Alnylam Pharmaceuticals Inc Rnai modulation of RSV and therapeutic uses thereof
EP2230517A1 (en) 2005-01-07 2010-09-22 Diadexus, Inc. OVR110 antibody compositions and methods of use
US20060217324A1 (en) * 2005-01-24 2006-09-28 Juergen Soutschek RNAi modulation of the Nogo-L or Nogo-R gene and uses thereof
JP2008528004A (en) * 2005-01-26 2008-07-31 ザ ジョンズ ホプキンス ユニバーシティー Anticancer DNA vaccine using plasmid encoding mutant oncoprotein antigen and calreticulin
TW200639252A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
EP2377951A1 (en) 2005-02-14 2011-10-19 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
JP2008530084A (en) * 2005-02-14 2008-08-07 株式会社Ｈｖｃ戦略研究所 Drugs to prevent cancer metastasis
EP2157182A3 (en) 2005-03-08 2012-04-25 Qiagen GmbH Modified short interfering RNA
US7947660B2 (en) 2005-03-11 2011-05-24 Alcon, Inc. RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
US8999943B2 (en) * 2005-03-14 2015-04-07 Board Of Regents, The University Of Texas System Antigene oligomers inhibit transcription
GB0505081D0 (en) * 2005-03-14 2005-04-20 Genomica Sau Downregulation of interleukin-12 expression by means of rnai technology
JP4585342B2 (en) * 2005-03-18 2010-11-24 株式会社資生堂 Method for screening substance for suppressing keratinization, substance screened by the same method, and method for suppressing keratinization
EP1877556B1 (en) * 2005-03-25 2011-09-14 Medtronic, Inc. Use of anti-tnf or anti-il1 rnai to suppress pro- inflammatory cytokine actions locally to treat pain
PL1866414T3 (en) * 2005-03-31 2012-10-31 Calando Pharmaceuticals Inc Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
US20090203055A1 (en) * 2005-04-18 2009-08-13 Massachusetts Institute Of Technology Compositions and methods for RNA interference with sialidase expression and uses thereof
US7902352B2 (en) 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
WO2006121960A2 (en) 2005-05-06 2006-11-16 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
WO2007008300A2 (en) * 2005-05-31 2007-01-18 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE Triblock copolymers for cytoplasmic delivery of gene-based drugs
US20070048293A1 (en) * 2005-05-31 2007-03-01 The Trustees Of The University Of Pennsylvania Manipulation of PTEN in T cells as a strategy to modulate immune responses
DK1888749T3 (en) * 2005-06-01 2015-01-05 Polyplus Transfection Oligonucleotides for RNA interference and their biological applications
JP2008545749A (en) * 2005-06-01 2008-12-18 デューク ユニバーシティ Methods for inhibiting intimal hyperplasia
CN100445381C (en) * 2005-06-10 2008-12-24 中国人民解放军军事医学科学院基础医学研究所 Preparation method for siRNA molecule with single chain polyA tail and application thereof
WO2006131925A2 (en) * 2005-06-10 2006-12-14 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
FI20050640A0 (en) * 2005-06-16 2005-06-16 Faron Pharmaceuticals Oy Compounds for treating or preventing diseases or disorders related to amine oxidases
CN101501055B (en) * 2005-06-23 2016-05-11 贝勒医学院 The adjusting of negativity immune-regulating factor and immunotherapy application
AU2006261732B2 (en) * 2005-06-27 2011-09-15 Alnylam Pharmaceuticals, Inc. RNAi modulation of HIF-1 and theraputic uses thereof
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
AU2006267841B2 (en) 2005-07-07 2011-12-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating H19, and methods of using same
US8703769B2 (en) 2005-07-15 2014-04-22 The University Of North Carolina At Chapel Hill Use of EGFR inhibitors to prevent or treat obesity
EP2204445B1 (en) * 2005-07-25 2013-01-02 RiboxX GmbH Methods and kit for primer-dependent amplification heterologous viral, eukaryotic and prokaryotic RNA
WO2007014370A2 (en) * 2005-07-28 2007-02-01 University Of Delaware Small regulatory rnas and methods of use
US7919583B2 (en) 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
US20070213257A1 (en) * 2005-08-12 2007-09-13 Nastech Pharmaceutical Company Inc. Compositions and methods for complexes of nucleic acids and peptides
WO2007022506A2 (en) 2005-08-18 2007-02-22 University Of Massachusetts Methods and compositions for treating neurological disease
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
EP1937312B1 (en) 2005-08-30 2016-06-29 Ionis Pharmaceuticals, Inc. Chimeric oligomeric compounds for modulation of splicing
US20090018097A1 (en) * 2005-09-02 2009-01-15 Mdrna, Inc Modification of double-stranded ribonucleic acid molecules
WO2007033058A2 (en) * 2005-09-13 2007-03-22 Trustees Of Dartmouth College Compositions and methods for regulating rna translation via cd154 ca-dinucleotide repeat
EP2980220A1 (en) 2005-09-20 2016-02-03 BASF Plant Science GmbH Improved methods controlling gene expression
FR2890859B1 (en) 2005-09-21 2012-12-21 Oreal DOUBLE-STRANDED RNA OLIGONUCLEOTIDE INHIBITING TYROSINASE EXPRESSION
US8933043B2 (en) * 2005-09-30 2015-01-13 St. Jude Children's Research Hospital Methods for regulation of p53 translation and function
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2007048046A2 (en) * 2005-10-20 2007-04-26 Protiva Biotherapeutics, Inc. Sirna silencing of filovirus gene expression
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
GB0521716D0 (en) * 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
US8076307B2 (en) * 2005-10-27 2011-12-13 National University Corporation NARA Institute of Science and Technology Formation/elongation of axon by inhibiting the expression or function of Singar and application to nerve regeneration
AU2006305886C1 (en) * 2005-10-28 2011-03-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of huntingtin gene
EP2395012B8 (en) * 2005-11-02 2018-06-06 Arbutus Biopharma Corporation Modified siRNA molecules and uses thereof
EP1942948A4 (en) * 2005-11-04 2010-03-03 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of nav1.8 gene
US8076308B2 (en) * 2005-11-07 2011-12-13 British Columbia Cancer Agency Inhibition of autophagy genes in cancer chemotherapy
US20100069461A1 (en) * 2005-11-09 2010-03-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
US7709456B2 (en) * 2005-11-17 2010-05-04 Board Of Regents, The University Of Texas System Modulation of gene expression by oligomers targeted to chromosomal DNA
US8603991B2 (en) 2005-11-18 2013-12-10 Gradalis, Inc. Individualized cancer therapy
US8916530B2 (en) * 2005-11-18 2014-12-23 Gradalis, Inc. Individualized cancer therapy
US20080125384A1 (en) * 2005-11-21 2008-05-29 Shuewi Yang Simultaneous silencing and restoration of gene function
JP4901753B2 (en) * 2005-11-24 2012-03-21 学校法人自治医科大学 Mitochondrial function of prohibitin 2 (PHB2)
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
CA2634286A1 (en) * 2005-12-22 2007-08-09 Samuel Jotham Reich Compositions and methods for regulating complement system
AR057252A1 (en) * 2005-12-27 2007-11-21 Alcon Mfg Ltd INHIBITION OF RHO KINASE MEDIATED BY ARNI FOR THE TREATMENT OF EYE DISORDERS
US8673873B1 (en) * 2005-12-28 2014-03-18 Alcon Research, Ltd. RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
CN101437933B (en) 2005-12-28 2013-11-06 斯克里普斯研究所 Natural antisense and non-coding RNA transcripts as drug targets
WO2007080457A2 (en) * 2005-12-30 2007-07-19 Institut Gustave Roussy Use of inhibitors of scinderin and/or of ephrin-a1 for treating tumors
US7884264B2 (en) 2006-01-17 2011-02-08 Biolex Therapeutics, Inc. Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in duckweed plants
US20090060921A1 (en) * 2006-01-17 2009-03-05 Biolex Therapeutics, Inc. Glycan-optimized anti-cd20 antibodies
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
NL2000439C2 (en) 2006-01-20 2009-03-16 Quark Biotech Therapeutic applications of inhibitors of RTP801.
EP3936621A1 (en) 2006-01-20 2022-01-12 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2007087451A2 (en) * 2006-01-25 2007-08-02 University Of Massachusetts Compositions and methods for enhancing discriminatory rna interference
JP2009524419A (en) * 2006-01-27 2009-07-02 サンタリス ファーマ アー／エス LNA modified phosphorothiolated oligonucleotides
US8229398B2 (en) * 2006-01-30 2012-07-24 Qualcomm Incorporated GSM authentication in a CDMA network
EP1989307B1 (en) * 2006-02-08 2012-08-08 Quark Pharmaceuticals, Inc. NOVEL TANDEM siRNAS
US7910566B2 (en) 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
FI20060246A0 (en) * 2006-03-16 2006-03-16 Jukka Westermarck A new growth stimulating protein and its use
WO2007109609A2 (en) * 2006-03-17 2007-09-27 The Board Of Trustees Of The University Of Illinois Method for inhibiting angiogenesis
WO2007107162A2 (en) 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
CA2644621A1 (en) * 2006-03-24 2007-10-04 Novartis Ag Dsrna compositions and methods for treating hpv infection
FR2898908A1 (en) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Process, useful to prepare differentiated avian cells from avian stem cells grown in culture medium, comprises induction of stem cells differentiation by inhibiting expression/activity of gene expressed in the stem cells e.g. Nanog gene
US20070238691A1 (en) * 2006-03-29 2007-10-11 Senesco Technologies, Inc. Inhibition of HIV replication and expression of p24 with eIF-5A
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
KR101547579B1 (en) 2006-03-31 2015-08-27 알닐람 파마슈티칼스 인코포레이티드 DsRNA for inhibiting expression of Eg5 gene
EP2007891A2 (en) * 2006-04-06 2008-12-31 DKFZ Deutsches Krebsforschungszentrum Method to inhibit the propagation of an undesired cell population
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
EP2010226B1 (en) 2006-04-07 2014-01-15 The Research Foundation of State University of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
WO2008108776A1 (en) * 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating b- cell malignancies
WO2007120883A2 (en) * 2006-04-12 2007-10-25 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
US20100055116A1 (en) * 2006-04-13 2010-03-04 Liou Hsiou-Chi Methods and Compositions for Targeting c-Rel
EP3266867A1 (en) 2006-04-14 2018-01-10 Cell Signaling Technology, Inc. Gene defects and mutant alk kinase in human solid tumors
EP2012815A4 (en) * 2006-04-14 2009-12-09 Massachusetts Inst Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
US7691824B2 (en) * 2006-04-28 2010-04-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the JC virus
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
WO2007134161A2 (en) * 2006-05-11 2007-11-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the pcsk9 gene
CA2652280C (en) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
WO2007133758A1 (en) * 2006-05-15 2007-11-22 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
US20070269892A1 (en) * 2006-05-18 2007-11-22 Nastech Pharmaceutical Company Inc. FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
CN101489566B (en) * 2006-05-19 2012-04-18 阿尔尼拉姆医药品有限公司 Rnai modulation of aha and therapeutic uses thereof
MX2008014437A (en) * 2006-05-19 2008-11-27 Scripps Research Inst Treatment of protein misfolding.
CA2653451C (en) * 2006-05-22 2015-12-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of ikk-b gene
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
US20070275923A1 (en) * 2006-05-25 2007-11-29 Nastech Pharmaceutical Company Inc. CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
GB0610542D0 (en) * 2006-05-26 2006-07-05 Medical Res Council Screening method
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
US7915399B2 (en) * 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
ES2390499T3 (en) * 2006-06-12 2012-11-13 Opko Pharmaceuticals, Llc Compositions and methods for inhibition of angiogenesis by sirna
WO2007147067A2 (en) * 2006-06-14 2007-12-21 Rosetta Inpharmatics Llc Methods and compositions for regulating cell cycle progression
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US8124752B2 (en) * 2006-07-10 2012-02-28 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the MYC gene
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
WO2008008986A2 (en) 2006-07-13 2008-01-17 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
JP4756271B2 (en) * 2006-07-18 2011-08-24 独立行政法人産業技術総合研究所 Cancer cell aging, apoptosis inducer
RU2553561C2 (en) * 2006-07-21 2015-06-20 Сайленс Терапьютикс Аг Means for inhibiting proteinkinase 3 expression
US20080039415A1 (en) * 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
DE102006039479A1 (en) 2006-08-23 2008-03-06 Febit Biotech Gmbh Programmable oligonucleotide synthesis
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
JP2010504350A (en) * 2006-09-19 2010-02-12 アシュラジェン インコーポレイテッド Genes and pathways regulated by miR-200 as targets for therapeutic intervention
WO2008036776A2 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
CA2663581C (en) 2006-09-21 2016-03-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the hamp gene
CA2663601C (en) 2006-09-22 2014-11-25 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by rna interference
EP2087110A2 (en) * 2006-10-11 2009-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Influenza targets
WO2008063760A2 (en) * 2006-10-18 2008-05-29 The University Of Texas M.D. Anderson Cancer Center Methods for treating cancer targeting transglutaminase
JP2010507387A (en) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド Novel siRNA and method of using the same
EP2061901A2 (en) 2006-10-31 2009-05-27 Noxxon Pharma AG Methods for detection of a single- or double-stranded nucleic acid molecule
WO2008053487A2 (en) 2006-11-01 2008-05-08 The Medical Research Fund At The Tel-Aviv Sourasky Medical Center Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
US9375440B2 (en) 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US8758998B2 (en) 2006-11-09 2014-06-24 Gradalis, Inc. Construction of bifunctional short hairpin RNA
US8252526B2 (en) * 2006-11-09 2012-08-28 Gradalis, Inc. ShRNA molecules and methods of use thereof
US8906874B2 (en) 2006-11-09 2014-12-09 Gradalis, Inc. Bi-functional shRNA targeting Stathmin 1 and uses thereof
US7988668B2 (en) 2006-11-21 2011-08-02 Medtronic, Inc. Microsyringe for pre-packaged delivery of pharmaceuticals
US8034921B2 (en) * 2006-11-21 2011-10-11 Alnylam Pharmaceuticals, Inc. IRNA agents targeting CCR5 expressing cells and uses thereof
US7819842B2 (en) 2006-11-21 2010-10-26 Medtronic, Inc. Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites
EP2087912B1 (en) * 2006-11-22 2017-05-10 The University of Tokyo Sirna carrier using disulfide-bridged polymeric micelle
AU2007355108B2 (en) 2006-11-27 2013-07-11 Patrys Limited Novel glycosylated peptide target in neoplastic cells
AU2007325283B2 (en) 2006-11-27 2012-08-30 Diadexus, Inc. Ovr110 antibody compositions and methods of use
WO2008067373A2 (en) * 2006-11-28 2008-06-05 Alcon Research, Ltd. RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS
US20080261907A1 (en) * 2006-11-30 2008-10-23 University Of Southern California Compositions and methods of sphingosine kinase inhibitors in radiation therapy of various cancers
WO2008073920A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2008076324A2 (en) * 2006-12-14 2008-06-26 Novartis Ag Compositions and methods to treat muscular & cardiovascular disorders
US20090175827A1 (en) * 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US7754698B2 (en) * 2007-01-09 2010-07-13 Isis Pharmaceuticals, Inc. Modulation of FR-alpha expression
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
CA2712056C (en) 2007-01-16 2016-06-21 The University Of Queensland Method of inducing an immune response
US20090074785A1 (en) * 2007-01-16 2009-03-19 Smith Jeffrey W Compositions and methods for treatment of colorectal cancer
CA2675967A1 (en) * 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusale M Nucleic acid constructs and methods for specific silencing of h19
US20080171906A1 (en) * 2007-01-16 2008-07-17 Everaerts Frank J L Tissue performance via hydrolysis and cross-linking
WO2008087558A2 (en) * 2007-01-17 2008-07-24 Institut De Recherches Cliniques De Montreal Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use
BRPI0806436A2 (en) 2007-01-26 2011-09-06 Univ Lousville Res Foundation Inc modification of exosomal components for use as a vaccine
WO2008093331A1 (en) * 2007-01-29 2008-08-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antibody conjugates for circumventing multi-drug resistance
US20100183696A1 (en) * 2007-01-30 2010-07-22 Allergan, Inc Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists
EP2121987B1 (en) 2007-02-09 2012-06-13 Northwestern University Particles for detecting intracellular targets
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
DE102007008596B4 (en) * 2007-02-15 2010-09-02 Friedrich-Schiller-Universität Jena Biologically active molecules based on PNA and siRNA, methods for their cell-specific activation and application kit for administration
AU2008218813B2 (en) * 2007-02-20 2014-04-17 Monsanto Technology, Llc Invertebrate microRNAs
WO2008106102A2 (en) 2007-02-26 2008-09-04 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
US20100292301A1 (en) * 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
WO2008109034A2 (en) * 2007-03-02 2008-09-12 The Trustees Of The University Of Pennsylvania Modulating pdx-1 with pcif1, methods and uses thereof
JP2010519913A (en) * 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド NUCLEIC ACID COMPOUND AND USE THEREOF FOR SUPPRESSING WNT GENE EXPRESSION
WO2008109357A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting apob gene expression and uses thereof
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
BRPI0809130A8 (en) 2007-03-21 2021-11-03 Brookhaven Science Ass Llc Combined hairpin-antisense compositions and methods for expression modulation
US7812002B2 (en) 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
PE20090064A1 (en) * 2007-03-26 2009-03-02 Novartis Ag DOUBLE-CHAIN RIBONUCLEIC ACID TO INHIBIT THE EXPRESSION OF THE HUMAN E6AP GENE AND THE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
JP5350360B2 (en) * 2007-03-29 2013-11-27 アルナイラム ファーマシューティカルズ， インコーポレイテッド Compositions and methods for inhibiting the expression of genes from Ebola
EP2144600A4 (en) 2007-04-04 2011-03-16 Massachusetts Inst Technology Poly (amino acid) targeting moieties
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
AU2008236566A1 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
CA2678055C (en) 2007-04-10 2016-02-16 Qiagen Gmbh Rna interference tags
US8808747B2 (en) * 2007-04-17 2014-08-19 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
US8877917B2 (en) 2007-04-23 2014-11-04 Alnylam Pharmaceuticals, Inc. Glycoconjugates of RNA interference agents
WO2008143774A2 (en) * 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
WO2008137115A1 (en) 2007-05-03 2008-11-13 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
JP5296328B2 (en) * 2007-05-09 2013-09-25 独立行政法人理化学研究所 Single-stranded circular RNA and method for producing the same
US20090053140A1 (en) * 2007-05-15 2009-02-26 Roderick Euan Milne Scott METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA(siRNA)
CA2684920A1 (en) * 2007-05-15 2008-11-27 Helicon Therapeutics, Inc. Methods of treating cognitive disorders by inhibition of gpr12
CN104480112B (en) 2007-05-22 2018-06-12 阿克丘勒斯治疗公司 For the UNA oligomer for the treatment of
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
IN2009KN04568A (en) 2007-06-01 2015-08-28 Univ Princeton
US9051391B2 (en) 2007-06-11 2015-06-09 Takara Bio Inc. Method for expression of specific gene
US20100273854A1 (en) * 2007-06-15 2010-10-28 Hagar Kalinski Compositions and methods for inhibiting nadph oxidase expression
AR066984A1 (en) 2007-06-15 2009-09-23 Novartis Ag INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA)
US8785408B2 (en) 2007-06-27 2014-07-22 Quark Pharmaceuticals, Inc. Compositions and methods for reducing or protecting against delayed graft function (DGF)
WO2009004995A1 (en) 2007-06-29 2009-01-08 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Method of fixing and expressing physiologically active substance
BRPI0814189A2 (en) * 2007-07-05 2015-03-03 Novartis Ag DOUBLE FILM RIBONUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND ITS USES, METHOD FOR INHIBITING PHOSPHYDYLINOSITOL 4-KINASE EXPRESSION, VECTOR AND USE OF A COMPOUND THAT SELECTIVELY INHIBITS PHOSPHTIDYLINOSITOL-4 PHASE.
EP2167692B1 (en) 2007-07-10 2013-05-22 Neurim Pharmaceuticals (1991) Ltd. Cd44 splice variants in neurodegenerative diseases
US8828960B2 (en) * 2007-07-17 2014-09-09 Idexx Laboratories, Inc. Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
JP2009033986A (en) * 2007-07-31 2009-02-19 Sumitomo Chemical Co Ltd USE OF car GENE AS TARGET GENE FOR INHIBITING GENE EXPRESSION BY RNA INTERFERENCE
EP2030615A3 (en) 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
US8501929B2 (en) * 2007-08-17 2013-08-06 Biochrom Pharma Inc. PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease
CA2735167A1 (en) * 2007-08-27 2009-03-05 Boston Biomedical, Inc. Composition of asymmetric rna duplex as microrna mimetic or inhibitor
US8637477B2 (en) * 2007-08-30 2014-01-28 Akshaya Bio Inc. Antigenic compositions and use of same in the targeted delivery of nucleic acids
WO2009032364A1 (en) * 2007-08-31 2009-03-12 Ghc Research Development Corporation Activation of nuclear factor-kappa b
US8183221B2 (en) 2007-09-05 2012-05-22 Medtronic, Inc. Suppression of SCN9A gene expression and/or function for the treatment of pain
JP5049713B2 (en) * 2007-09-14 2012-10-17 株式会社コナミデジタルエンタテインメント GAME SYSTEM, GAME DEVICE COMPRISING THE SAME, AND PROBLEM NOTIFICATION DEVICE
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
JP2010539245A (en) * 2007-09-14 2010-12-16 日東電工株式会社 Drug carrier
JP5723154B2 (en) 2007-09-19 2015-05-27 アプライド バイオシステムズ リミテッド ライアビリティー カンパニー SiRNA sequence-independent modification format for reducing the influence of off-target phenotype in RNAi and its stabilized form
EP2197454A4 (en) * 2007-09-25 2012-07-04 Idexx Lab Inc Pharmaceutical compositions for administering oligonucleotides
US20100136026A1 (en) * 2007-09-26 2010-06-03 Kerr William G Ship Inhibition to Direct Hematopoietic Stem Cells and Induce Extramedullary Hematopoiesis
DK2644192T3 (en) 2007-09-28 2017-06-26 Pfizer Cancer cell targeting using nanoparticles
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
US8614309B2 (en) 2007-10-03 2013-12-24 Quark Pharmaceuticals, Inc. Double-stranded RNA directed to CASP2 and methods of use thereof
EP2205746A4 (en) * 2007-10-04 2010-12-22 Univ Texas Modulating gene expression with agrna and gapmers targeting antisense transcripts
ES2627233T3 (en) 2007-10-12 2017-07-27 Massachusetts Institute Of Technology Vaccine Nanotechnology
CA2702686C (en) 2007-10-18 2023-04-04 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
US8097712B2 (en) * 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
US20100098664A1 (en) * 2007-11-28 2010-04-22 Mathieu Jean-Francois Desclaux Lentiviral vectors allowing RNAi mediated inhibition of GFAP and vimentin expression
US8324369B2 (en) * 2007-11-30 2012-12-04 Baylor College Of Medicine Dendritic cell vaccine compositions and uses of same
US8071562B2 (en) * 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
US8507455B2 (en) * 2007-12-04 2013-08-13 Alnylam Pharmaceuticals, Inc. Folate conjugates
CA2910760C (en) * 2007-12-04 2019-07-09 Muthiah Manoharan Targeting lipids
JP5530933B2 (en) 2007-12-10 2014-06-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド Compositions and methods for inhibiting factor VII gene expression
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
US20110105584A1 (en) * 2007-12-12 2011-05-05 Elena Feinstein Rtp80il sirna compounds and methods of use thereof
US20090238772A1 (en) * 2007-12-13 2009-09-24 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection
WO2009079399A2 (en) * 2007-12-14 2009-06-25 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
US7845686B2 (en) * 2007-12-17 2010-12-07 S & B Technical Products, Inc. Restrained pipe joining system for plastic pipe
KR100949791B1 (en) * 2007-12-18 2010-03-30 이동기 Novel siRNA Structure for Minimizing Off-target Effects and Relaxing Saturation of RNAi Machinery and the Use Thereof
US20090192114A1 (en) * 2007-12-21 2009-07-30 Dmitriy Ovcharenko miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
WO2009090639A2 (en) * 2008-01-15 2009-07-23 Quark Pharmaceuticals, Inc. Sirna compounds and methods of use thereof
AU2009241591A1 (en) * 2008-01-31 2009-11-05 Alnylam Pharmaceuticals, Inc. Optimized methods for delivery of DSRNA targeting the PCSK9 gene
US20090263803A1 (en) * 2008-02-08 2009-10-22 Sylvie Beaudenon Mirnas differentially expressed in lymph nodes from cancer patients
US10131904B2 (en) 2008-02-11 2018-11-20 Rxi Pharmaceuticals Corporation Modified RNAi polynucleotides and uses thereof
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
WO2009137128A2 (en) 2008-02-12 2009-11-12 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd45 gene
US7977321B2 (en) * 2008-02-12 2011-07-12 University Of Tennessee Research Foundation Small interfering RNAs targeting feline herpes virus
DE102009043743B4 (en) 2009-03-13 2016-10-13 Friedrich-Schiller-Universität Jena Cell-specific molecules based on siRNA as well as application kits for their production and use
EP2247748A2 (en) * 2008-02-13 2010-11-10 Elan Pharma International Limited Alpha-synuclein kinase
WO2009103067A2 (en) * 2008-02-14 2009-08-20 The Children's Hospital Of Philadelphia Compositions and methods to treat asthma
JP2011518117A (en) * 2008-03-05 2011-06-23 アルナイラム ファーマシューティカルズ， インコーポレイテッド Compositions and methods for inhibiting expression of Eg5 and VEGF genes
US20090233297A1 (en) * 2008-03-06 2009-09-17 Elizabeth Mambo Microrna markers for recurrence of colorectal cancer
US8202848B2 (en) * 2008-03-17 2012-06-19 Board Of Regents, The University Of Texas System Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
CA2718765A1 (en) * 2008-03-20 2009-09-24 Quark Pharmaceuticals, Inc. Novel sirna compounds for inhibiting rtp801
EP2271757A2 (en) * 2008-03-26 2011-01-12 Asuragen, INC. Compositions and methods related to mir-16 and therapy of prostate cancer
EP2105145A1 (en) * 2008-03-27 2009-09-30 ETH Zürich Method for muscle-specific delivery lipid-conjugated oligonucleotides
ES2605618T3 (en) * 2008-03-31 2017-03-15 National Institute Of Advanced Industrial Science And Technology Double-stranded, lipid-modified RNA with high RNA interference effect
TWI348916B (en) * 2008-04-03 2011-09-21 Univ Nat Taiwan A novel treatment tool for cancer: rna interference of bcas2
WO2009126726A1 (en) * 2008-04-08 2009-10-15 Asuragen, Inc Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
US8309614B2 (en) 2008-04-11 2012-11-13 Cedars-Sinai Medical Center Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery
CA2721183C (en) 2008-04-11 2019-07-16 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
US8278287B2 (en) * 2008-04-15 2012-10-02 Quark Pharmaceuticals Inc. siRNA compounds for inhibiting NRF2
WO2009129465A2 (en) * 2008-04-17 2009-10-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of xbp-1 gene
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
KR20170005148A (en) 2008-04-21 2017-01-11 티슈 리제너레이션 쎄라퓨틱스, 인코포레이티드 Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
WO2009134443A2 (en) * 2008-05-02 2009-11-05 The Brigham And Women's Hospital, Inc. Rna-induced translational silencing and cellular apoptosis
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
WO2009146417A1 (en) * 2008-05-30 2009-12-03 Sigma-Aldrich Co. Compositions and methods for specifically silencing a target nucleic acid
WO2009149182A1 (en) 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
US20090305611A1 (en) * 2008-06-06 2009-12-10 Flow International Corporation Device and method for improving accuracy of a high-pressure fluid jet apparatus
WO2009147684A2 (en) 2008-06-06 2009-12-10 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
WO2009150156A1 (en) * 2008-06-13 2009-12-17 Riboxx Gmbh Method for enzymatic synthesis of chemically modified rna
US8361510B2 (en) * 2008-06-16 2013-01-29 Georgia Tech Research Corporation Nanogels for cellular delivery of therapeutics
TWI455944B (en) 2008-07-01 2014-10-11 Daiichi Sankyo Co Ltd Double-stranded polynucleotides
WO2010006342A2 (en) * 2008-07-11 2010-01-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of gsk-3 genes
WO2010008562A2 (en) 2008-07-16 2010-01-21 Recombinetics Methods and materials for producing transgenic animals
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
US8039658B2 (en) * 2008-07-25 2011-10-18 Air Products And Chemicals, Inc. Removal of trace arsenic impurities from triethylphosphate (TEPO)
US8212019B2 (en) * 2008-07-30 2012-07-03 University Of Massachusetts Nucleic acid silencing sequences
US9433684B2 (en) 2008-08-19 2016-09-06 Nektar Therapeutics Conjugates of small-interfering nucleic acids
EP3081648A1 (en) 2008-08-25 2016-10-19 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
WO2011028218A1 (en) 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Process for triphosphate oligonucleotide synthesis
PT2334794T (en) * 2008-09-15 2017-02-15 Harvard College Modulation of bcl11a for treatment of hemoglobinopathies
JP2012502991A (en) 2008-09-22 2012-02-02 アールエックスアイ ファーマシューティカルズ コーポレーション RNA interference in dermal applications
JP2012513953A (en) 2008-09-23 2012-06-21 アルニラム ファーマスーティカルズ インコーポレイテッド Chemical modification of monomers and oligonucleotides using cycloaddition
EP2334793B1 (en) 2008-09-25 2016-04-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of serum amyloid a gene
US8592570B2 (en) * 2008-10-06 2013-11-26 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of an RNA from West Nile virus
US9388413B2 (en) 2008-10-08 2016-07-12 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
WO2010042292A1 (en) * 2008-10-08 2010-04-15 Trustees Of Dartmouth College Method for selectively inhibiting the activity of acat1 in the treatment of alzheimer's disease
US9388414B2 (en) 2008-10-08 2016-07-12 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
US8802646B2 (en) * 2008-10-08 2014-08-12 Trustees Of Dartmouth College Method for selectively inhibiting the activity of ACAT1 in the treatment of alzheimer's disease
US9149492B2 (en) 2008-10-08 2015-10-06 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease
WO2010042877A1 (en) 2008-10-09 2010-04-15 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US9458472B2 (en) * 2008-10-15 2016-10-04 Massachusetts Institute Of Technology Detection and destruction of cancer cells using programmed genetic vectors
JP2012505657A (en) 2008-10-15 2012-03-08 ソマジェニックス インク． Short hairpin RNA for gene expression inhibition
EA029762B1 (en) 2008-10-20 2018-05-31 Элнилэм Фармасьютикалз, Инк. Compositions and methods for inhibiting expression of transthyretin
US20100168205A1 (en) * 2008-10-23 2010-07-01 Alnylam Pharmaceuticals, Inc. Methods and Compositions for Prevention or Treatment of RSV Infection Using Modified Duplex RNA Molecules
US20110190380A1 (en) * 2008-10-23 2011-08-04 Elena Feinstein Methods for delivery of sirna to bone marrow cells and uses thereof
KR20220150995A (en) 2008-11-10 2022-11-11 알닐람 파마슈티칼스 인코포레이티드 Novel lipids and compositions for the delivery of therapeutics
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
WO2010057020A2 (en) * 2008-11-13 2010-05-20 Modgene, Llc Modification of amyloid-beta load in non-brain tissue
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
AU2009316853A1 (en) 2008-11-21 2010-05-27 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
DK2365803T3 (en) 2008-11-24 2018-01-22 Univ Northwestern POLYVALENT RNA NANOPARTICLE COMPOSITIONS
EP2191834A1 (en) * 2008-11-26 2010-06-02 Centre National De La Recherche Scientifique (Cnrs) Compositions and methods for treating retrovirus infections
CN104673798B (en) 2008-12-03 2018-03-20 阿克丘勒斯治疗公司 UsiRNA compounds
US20100291188A1 (en) * 2008-12-04 2010-11-18 Musc Foundation For Research Development Periostin Inhibitory Compositions for Myocardial Regeneration, Methods of Delivery, and Methods of Using Same
NZ593743A (en) 2008-12-04 2012-07-27 Opko Ophthalmics Llc Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
SG10201708690SA (en) 2008-12-09 2017-12-28 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010068816A1 (en) * 2008-12-10 2010-06-17 Alnylam Pharmaceuticals, Inc. Gnaq targeted dsrna compositions and methods for inhibiting expression
US8664188B2 (en) * 2008-12-11 2014-03-04 Xiangxue Group (Hong Kong) Company Limited siRNA compositions and methods for potently inhibiting viral infection
EP2377934A4 (en) * 2008-12-12 2012-09-26 Kureha Corp Pharmaceutical composition for treatment of cancer and asthma
US20100233172A1 (en) * 2008-12-16 2010-09-16 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
US20110288155A1 (en) 2008-12-18 2011-11-24 Elena Feinstein Sirna compounds and methods of use thereof
CN102300556B (en) 2008-12-26 2015-04-29 株式会社三养生物制药 Pharmaceutical composition containing an anionic drug, and a production method therefor
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2010083532A1 (en) * 2009-01-19 2010-07-22 The Research Foundaton Of State University Of New York Fatty acid binding proteins as drug targets for modulation of endocannabinoids
US8741862B2 (en) * 2009-01-20 2014-06-03 Vib Vzw PHD2 inhibition for blood vessel normalization, and uses thereof
US9023820B2 (en) 2009-01-26 2015-05-05 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein C-III expression
MX2011007776A (en) * 2009-02-03 2011-08-12 Hoffmann La Roche Compositions and methods for inhibiting expression of ptp1b genes.
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
PT2881402T (en) 2009-02-12 2017-08-23 Cell Signaling Technology Inc Mutant ros expression in human liver cancer
EP2401375B1 (en) * 2009-02-24 2017-08-23 RiboxX GmbH Improved design of small-interfering rna
US8975389B2 (en) 2009-03-02 2015-03-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
MX2011009724A (en) * 2009-03-19 2011-10-14 Merck Sharp & Dohme RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING.
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
WO2010111198A1 (en) 2009-03-23 2010-09-30 Quark Pharmaceuticals, Inc. Compounds compositions and methods of treating cancer and fibrotic diseases
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
EP2421972A2 (en) * 2009-04-24 2012-02-29 The Board of Regents of The University of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
US8367350B2 (en) 2009-04-29 2013-02-05 Morehouse School Of Medicine Compositions and methods for diagnosis, prognosis and management of malaria
WO2010128465A1 (en) 2009-05-05 2010-11-11 Beeologics, Llc Prevention and treatment of nosema disease in bees
US8933049B2 (en) * 2009-05-05 2015-01-13 Medical Diagnostic Laboratories, Llc Repressor on IFN-λ promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-λ gene activity
WO2010129791A1 (en) * 2009-05-06 2010-11-11 University Of Medicine And Dentistry Of New Jersey Rna targeting in alpha-synucleinopathies
WO2010130771A2 (en) * 2009-05-15 2010-11-18 F. Hoffmann-La Roche Ag Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes
WO2011005363A2 (en) * 2009-05-18 2011-01-13 Ensysce Biosciences, Inc. Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
US20120128673A1 (en) 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
US20100304995A1 (en) * 2009-05-22 2010-12-02 Li Shen Arrays and Methods for Reverse Genetic Functional Analysis
CN102575252B (en) 2009-06-01 2016-04-20 光环生物干扰疗法公司 For polynucleotide, the compoistion and method of use of multivalence RNA interference
WO2010140024A1 (en) * 2009-06-03 2010-12-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for diagnosing and treating a renal disease in an individual
US9187757B2 (en) 2009-06-05 2015-11-17 University Of Florida Research Foundation, Inc. Isolation and targeted suppression of lignin biosynthetic genes
EP2440214A4 (en) 2009-06-08 2013-07-31 Quark Pharmaceuticals Inc Methods for treating chronic kidney disease
CN104873464B (en) 2009-06-10 2018-06-22 阿布特斯生物制药公司 Improved lipid formulations
AU2010259295B2 (en) 2009-06-10 2015-05-07 Temasek Life Sciences Laboratory Limited Virus induced gene silencing (VIGS) for functional analysis of genes in cotton.
CN104651408A (en) * 2009-06-15 2015-05-27 阿尔尼拉姆医药品有限公司 Lipid formulated siRNA targeted to PCSK9 gene
WO2010147992A1 (en) 2009-06-15 2010-12-23 Alnylam Pharmaceuticals, Inc. Methods for increasing efficacy of lipid formulated sirna
US20100324124A1 (en) * 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Compositions and methods relating to DNA-based particles
US20100323018A1 (en) * 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Branched DNA/RNA monomers and uses thereof
GB0910723D0 (en) * 2009-06-22 2009-08-05 Sylentis Sau Novel drugs for inhibition of gene expression
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8283333B2 (en) 2009-07-01 2012-10-09 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
WO2011008730A2 (en) 2009-07-13 2011-01-20 Somagenics Inc. Chemical modification of small hairpin rnas for inhibition of gene expression
US8716464B2 (en) * 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
ES2768990T3 (en) 2009-07-20 2020-06-24 Bristol Myers Squibb Co Combination of anti-CTLA4 antibodies with gemcitabine for the synergistic treatment of proliferative diseases
EP3381937A3 (en) 2009-08-13 2018-10-31 The Johns Hopkins University Methods of modulating immune function
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
EP3811950A1 (en) 2009-08-24 2021-04-28 Phigenix, Inc. Targeting pax2 for the treatment of breast cancer
EP2475388B1 (en) 2009-09-10 2017-11-08 Merck Sharp & Dohme Corp. Use of il-33 antagonists to treat fibrotic disease
WO2011032100A1 (en) 2009-09-11 2011-03-17 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Inhibitors of kshv vil6 and human il6
EP2295543A1 (en) 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
CN102639115A (en) 2009-09-15 2012-08-15 阿尔尼拉姆医药品有限公司 Lipid formulated compositions and methods for inhibiting expression of EG5 and VEGF genes
WO2011035065A1 (en) 2009-09-17 2011-03-24 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
US9187746B2 (en) 2009-09-22 2015-11-17 Alnylam Pharmaceuticals, Inc. Dual targeting siRNA agents
WO2011038160A2 (en) * 2009-09-23 2011-03-31 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
US20150025122A1 (en) 2009-10-12 2015-01-22 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
US9101643B2 (en) 2009-11-03 2015-08-11 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
US9799416B2 (en) * 2009-11-06 2017-10-24 Terrapower, Llc Methods and systems for migrating fuel assemblies in a nuclear fission reactor
CN102666856B (en) 2009-11-08 2016-04-06 夸克制药公司 Be directed to the purposes of double-stranded RNA compound in the medicine manufacturing treatment neuropathic pain of RhoA target gene
EP3037435B1 (en) 2009-11-17 2019-08-07 MUSC Foundation for Research Development Human monoclonal antibodies to human nucleolin
JP2013511990A (en) 2009-11-26 2013-04-11 クォーク ファーマシューティカルズ インコーポレーティッド SiRNA compounds containing terminal substitutions
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
KR101692063B1 (en) * 2009-12-09 2017-01-03 닛토덴코 가부시키가이샤 MODULATION OF hsp47 EXPRESSION
US8778904B2 (en) 2009-12-09 2014-07-15 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the CNS
WO2011072240A1 (en) 2009-12-10 2011-06-16 Cedars-Sinai Medical Center Drug delivery of temozolomide for systemic based treatment of cancer
EP2336171A1 (en) 2009-12-11 2011-06-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel targets for the treatment of proliferative diseases
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
AR079494A1 (en) 2009-12-18 2012-02-01 Novartis Ag ORGANIC COMPOSITIONS TO TREAT DISEASES RELATED TO THE HEAT SHOCK FACTOR 1 HSF1
US20130017223A1 (en) 2009-12-18 2013-01-17 The University Of British Columbia Methods and compositions for delivery of nucleic acids
CA2784547A1 (en) 2009-12-23 2011-06-30 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Influenza targets
CN108295087B (en) 2009-12-23 2021-01-15 格兰达利斯有限公司 Furin-knockdown and GM-CSF-enhanced (FANG) cancer vaccines
US20130023578A1 (en) 2009-12-31 2013-01-24 Samyang Biopharmaceuticals Corporation siRNA for inhibition of c-Met expression and anticancer composition containing the same
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
TW201124159A (en) * 2010-01-07 2011-07-16 Univ Nat Cheng Kung Small interference RNA molecule and applications thereof
WO2011085347A2 (en) * 2010-01-11 2011-07-14 Opko Curna, Llc Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
WO2011088058A1 (en) * 2010-01-12 2011-07-21 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expressions of factor vii and pten genes
DE102010004957A1 (en) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologically active molecules for influencing virus, bacterial, parasite-infected cells and / or tumor cells and methods for their use
WO2011094580A2 (en) 2010-01-28 2011-08-04 Alnylam Pharmaceuticals, Inc. Chelated copper for use in the preparation of conjugated oligonucleotides
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
US8722641B2 (en) 2010-01-29 2014-05-13 St. Jude Children's Research Hospital Oligonucleotides which inhibit p53 induction in response to cellular stress
EA201201113A1 (en) 2010-02-10 2013-03-29 Новартис Аг METHODS AND CONNECTIONS FOR GROWTH OF MUSCLE
US9186370B2 (en) * 2010-03-19 2015-11-17 University Of South Alabama Methods and compositions for the treatment of cancer
BR112012024049A2 (en) 2010-03-24 2017-03-01 Rxi Pharmaceuticals Corp rna interference on dermal and fibrotic indications
WO2011119871A1 (en) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
WO2011119852A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
US8455455B1 (en) 2010-03-31 2013-06-04 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes involved in hemorrhagic fever
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
WO2011133868A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Conformationally restricted dinucleotide monomers and oligonucleotides
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
ES2625689T3 (en) 2010-04-29 2017-07-20 Ionis Pharmaceuticals, Inc. Modulation of transthyretin expression
EP2563359A1 (en) 2010-04-30 2013-03-06 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
EP3138915A1 (en) 2010-05-04 2017-03-08 The Brigham and Women's Hospital, Inc. Detection and treatment of fibrosis
US8563243B2 (en) * 2010-05-12 2013-10-22 University Of South Carolina Methods for affecting homology-directed DNA double stranded break repair
NO2575876T3 (en) 2010-05-26 2018-05-05
EP2390327A1 (en) 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
DE102010022937A1 (en) 2010-06-04 2011-12-08 Universitätsklinikum Jena Cell-specific activatable biologically active molecules based on siRNA, methods for their activation and application kit for administration
US20130236968A1 (en) 2010-06-21 2013-09-12 Alnylam Pharmaceuticals, Inc. Multifunctional copolymers for nucleic acid delivery
KR101553753B1 (en) 2010-06-24 2015-09-16 쿠아크 파마수티칼스 인코퍼레이티드 Double stranded rna compounds to rhoa and use thereof
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
KR20130137160A (en) 2010-08-24 2013-12-16 머크 샤프 앤드 돔 코포레이션 Single-stranded rnai agents containing an internal, non-nucleic acid spacer
EP2622076A1 (en) 2010-09-30 2013-08-07 University of Zürich Treatment of b-cell lymphoma with microrna
SG189280A1 (en) * 2010-10-07 2013-05-31 Agency Science Tech & Res Parp-1 inhibitors
WO2012051491A1 (en) 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
CA2818662C (en) 2010-10-22 2021-07-06 Sungkyunkwan University Foundation For Corporate Collaboration Nucleic acid molecule inducing rna interference, and uses thereof
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
CA2818024C (en) 2010-12-06 2019-09-24 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
WO2012102793A2 (en) 2010-12-10 2012-08-02 Zirus, Inc. Mammalian genes involved in toxicity and infection
US9617542B2 (en) * 2010-12-14 2017-04-11 The United States of America, as representd by The Secretary of Agriculture Lepidopteran moth control using double-stranded RNA constructs
US9623041B2 (en) 2010-12-30 2017-04-18 Cedars-Sinai Medical Center Polymalic acid-based nanobiopolymer compositions
BR112013017585A2 (en) 2011-01-10 2020-11-24 The Regents Of The University Of Michigan stem cell factor inhibitor
US20150018408A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
WO2012099755A1 (en) 2011-01-11 2012-07-26 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
DE102011009470A1 (en) 2011-01-21 2012-08-09 Friedrich-Schiller-Universität Jena Biologically active nucleotide molecules for the targeted killing of cells, use thereof and application kit
TWI593416B (en) 2011-02-02 2017-08-01 艾克厘德製藥公司 Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
AU2012212105A1 (en) 2011-02-03 2013-09-12 Mirna Therapeutics, Inc. Synthetic mimics of miR-124
US9487778B2 (en) 2011-03-03 2016-11-08 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
US9233121B2 (en) * 2011-03-11 2016-01-12 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of cancer
JP2014510526A (en) 2011-03-15 2014-05-01 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション Diagnosis and treatment of vascular-related macular disease and its symptoms
WO2012135696A2 (en) * 2011-04-01 2012-10-04 University Of South Alabama Methods and compositions for the diagnosis, classification, and treatment of cancer
AU2012242784B2 (en) 2011-04-12 2017-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use
CN105886506A (en) 2011-04-13 2016-08-24 Isis制药公司 Antisense modulation of PTP1B expression
US8716257B2 (en) * 2011-04-15 2014-05-06 Sutter West Bay Hospitals CMV gene products promote cancer stem cell growth
WO2012142622A1 (en) * 2011-04-15 2012-10-18 Molecular Transfer, Inc. Agents for improved delivery of nucleic acids to eukaryotic cells
MX2013013329A (en) 2011-05-20 2014-04-16 Us Government Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof.
US9452219B2 (en) 2011-06-02 2016-09-27 University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
RU2631805C2 (en) 2011-06-21 2017-09-26 Элнилэм Фармасьютикалз, Инк. Compositions and methods for apolipoprotein c-iii (apoc3) gene expression inhibition
US9228188B2 (en) 2011-06-21 2016-01-05 Alnylam Pharmaceuticals, Inc. Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
EP3388068A1 (en) 2011-06-21 2018-10-17 Alnylam Pharmaceuticals, Inc. Composition and methods for inhibition of expression of protein c (proc) genes
CN103890000B (en) 2011-06-21 2017-09-01 阿尔尼拉姆医药品有限公司 (ANGPTL3) the iRNA compositions of angiopoietin-like 3 and its application method
WO2013001372A2 (en) 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
MX340536B (en) 2011-07-06 2016-07-13 Sykehuset Sorlandet Hf Egfr targeted therapy.
WO2013006861A1 (en) 2011-07-07 2013-01-10 University Of Georgia Research Foundation, Inc. Sorghum grain shattering gene and uses thereof in altering seed dispersal
US8853181B2 (en) 2011-07-21 2014-10-07 Albert Einstein College Of Medicine Of Yeshiva University Fidgetin-like 2 as a target to enhance wound healing
DE102011118024A1 (en) 2011-08-01 2013-02-07 Technische Universität Dresden New procaspase 1 expression inhibitor, useful for preventing and/or treating inflammatory diseases, which are autoinflammatory diseases
CA2847726C (en) 2011-09-06 2023-04-04 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. The mirna-212/132 family as a therapeutic target
JP2014527072A (en) 2011-09-09 2014-10-09 バイオメド リアルティー， エル．ピー． Methods and compositions for controlling the assembly of viral proteins
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
WO2013049328A1 (en) 2011-09-27 2013-04-04 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
US9951349B2 (en) 2011-09-27 2018-04-24 Yale University Compositions and methods for transient expression of recombinant RNA
KR102011048B1 (en) 2011-10-18 2019-08-14 다이서나 파마수이티컬, 인크. Amine cationic lipids and uses thereof
US20140323549A1 (en) 2011-11-08 2014-10-30 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
EP2725103A3 (en) * 2011-11-14 2016-01-06 Silenseed Ltd Methods and compositions for treating prostate cancer
KR102385013B1 (en) 2011-11-18 2022-04-12 알닐람 파마슈티칼스 인코포레이티드 RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
WO2013082529A1 (en) 2011-12-02 2013-06-06 Yale University Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
EP2797632A1 (en) 2012-01-01 2014-11-05 QBI Enterprises Ltd. Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
US9464291B2 (en) * 2012-01-06 2016-10-11 University Of South Alabama Methods and compositions for the treatment of cancer
CN104302768A (en) 2012-01-09 2015-01-21 诺华股份有限公司 Rnai agents to treat beta-catenin related diseases
CA2858630A1 (en) 2012-01-12 2013-07-18 Quark Pharmaceuticals, Inc. Combination therapy for treating hearing and balance disorders
WO2013112458A1 (en) 2012-01-24 2013-08-01 Beth Israel Deaconess Medical Center, Inc. Novel chrebp isoforms and methods using the same
US10105351B2 (en) 2012-03-14 2018-10-23 University Of Central Florida Research Foundation, Inc. Neurofibromatoses therapeutic agents and screening for same
US20150031750A1 (en) 2012-03-15 2015-01-29 The Scripps Research Institute Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP3336181B1 (en) 2012-04-18 2022-01-12 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
DK2853597T3 (en) 2012-05-22 2019-04-08 Olix Pharmaceuticals Inc RNA INTERFERENCE-INducing NUCLEIC ACID MOLECULES WITH CELL PENETENING EQUIPMENT AND USE THEREOF
EP2867368B1 (en) 2012-07-06 2022-01-12 Institut Gustave Roussy Simultaneous detection of cannibalism and senescence as prognostic marker for cancer
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
CA2883130A1 (en) 2012-08-31 2014-03-06 The General Hospital Corporation Biotin complexes for treatment and diagnosis of alzheimer's disease
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
WO2014037686A1 (en) 2012-09-05 2014-03-13 Sylentis S.A.U. Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
US9611474B2 (en) 2012-09-12 2017-04-04 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof
WO2014043292A1 (en) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof
ES2813340T3 (en) 2012-09-21 2021-03-23 Intensity Therapeutics Inc Cancer treatment method
EP2904119B1 (en) * 2012-10-02 2020-06-17 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
WO2014055825A1 (en) 2012-10-04 2014-04-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services A formulation of mycobacterial components as an adjuvant for inducing th17 responses
WO2014068072A1 (en) 2012-10-31 2014-05-08 Institut Gustave-Roussy Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
JP6391582B2 (en) * 2012-11-13 2018-09-19 コディアック バイオサイエンシズ インコーポレイテッド Methods for delivering therapeutic agents
DE102012022596B4 (en) 2012-11-15 2017-05-04 Friedrich-Schiller-Universität Jena New cell-specific effective nucleotide molecules and application kit for their application
PL2920201T3 (en) 2012-11-15 2020-10-05 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
ES2884925T3 (en) 2012-11-27 2021-12-13 Childrens Medical Ct Corp Distal regulatory elements of BCL11A as targets for fetal hemoglobin reinduction
US9970002B2 (en) 2012-12-12 2018-05-15 Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
EP2935333A1 (en) 2012-12-21 2015-10-28 Sykehuset Sorlandet HF Egfr targeted therapy of neurological disorders and pain
US9206423B2 (en) * 2012-12-30 2015-12-08 The Regents Of The University Of California Methods of modulating compliance of the trabecular meshwork
US10258682B2 (en) 2013-01-16 2019-04-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Attenuated chlamydia vaccine
DE102013003869B4 (en) 2013-02-27 2016-11-24 Friedrich-Schiller-Universität Jena A method for the targeted killing of cells by mRNA binding aligned nucleotide molecules and nucleotide molecules and application kit for such use
CA3120574A1 (en) 2013-03-14 2014-09-25 Dicerna Pharmaceuticals, Inc. Process for formulating an anionic agent
WO2014150751A2 (en) * 2013-03-15 2014-09-25 Novartis Ag Biomarkers associated with brm inhibition
CA2906100A1 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Treating th2-mediated diseases by inhibition of bromodomains
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
CA2918194C (en) 2013-03-27 2022-12-06 The General Hospital Corporation Methods and agents for treating alzheimer's disease
US20160146806A1 (en) 2013-05-17 2016-05-26 Amplimmune, Inc. Receptors for b7-h4
US10220053B2 (en) 2013-06-25 2019-03-05 University Of Canberra Methods and compositions for modulating cancer stem cells
TW201534578A (en) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd Novel lipid
CA2918387C (en) 2013-07-19 2021-11-02 Monsanto Technology Llc Compositions and methods for controlling leptinotarsa
US10711106B2 (en) 2013-07-25 2020-07-14 The University Of Chicago High aspect ratio nanofibril materials
WO2015015498A1 (en) 2013-07-31 2015-02-05 Qbi Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
EP3027222A1 (en) 2013-07-31 2016-06-08 QBI Enterprises Ltd. Sphingolipid-polyalkylamine-oligonucleotide compounds
NZ716816A (en) 2013-08-28 2022-05-27 Ionis Pharmaceuticals Inc Modulation of prekallikrein (pkk) expression
KR102435648B1 (en) 2013-09-11 2022-08-25 이글 바이오로직스 인코퍼레이티드 Liquid protein formulations containing viscosity-lowering agents
AU2014324092B2 (en) 2013-09-18 2020-02-06 Epiaxis Therapeutics Pty Ltd Stem cell modulation II
AU2014329560B2 (en) 2013-10-04 2017-03-02 Novartis Ag 3'end caps for RNAi agents for use in RNA interference
EP3052107B1 (en) 2013-10-04 2018-05-02 Novartis AG Organic compounds to treat hepatitis b virus
EP2865757A1 (en) 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene.
EP2865756A1 (en) 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene.
EP2865758A1 (en) 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
US10004814B2 (en) 2013-11-11 2018-06-26 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
EP3071590A4 (en) 2013-11-21 2017-07-19 SeNA Research, Inc. Methods for structural determination of selenium derivatized nucleic acid complexes
RU2744194C2 (en) 2013-12-02 2021-03-03 Фио Фармасьютикалс Корп Cancer immunotherapy
EP3077511A4 (en) 2013-12-06 2017-07-05 Dicerna Pharmaceuticals Inc. Methods and compositions for the specific inhibition of transthyretin (ttr) by double-stranded rna
CN104830906B (en) 2014-02-12 2018-09-04 北京维通达生物技术有限公司 A method of reprogramming obtains functional people's liver parenchymal cell
US10011837B2 (en) 2014-03-04 2018-07-03 Sylentis Sau SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
DK3693384T3 (en) 2014-03-11 2024-04-15 Cellectis Method for generating T cells with compatibility for allogeneic transplantation
EP3119887B1 (en) * 2014-03-20 2019-02-20 Oommen Varghese Improved small interfering ribonucleic acid molecules
WO2015148580A2 (en) 2014-03-25 2015-10-01 Arcturus Therapeutics, Inc. Una oligomers having reduced off-target effects in gene silencing
US9856475B2 (en) 2014-03-25 2018-01-02 Arcturus Therapeutics, Inc. Formulations for treating amyloidosis
WO2015148582A1 (en) 2014-03-25 2015-10-01 Arcturus Therapeutics, Inc. Transthyretin allele selective una oligomers for gene silencing
CN110506752B (en) 2014-04-01 2022-02-18 孟山都技术公司 Compositions and methods for controlling insect pests
AU2015240761B2 (en) 2014-04-01 2019-09-12 Biogen Ma Inc. Compositions for modulating SOD-1 expression
SG10201809290SA (en) 2014-04-25 2019-01-30 Childrens Medical Ct Corp Compositions and Methods to Treating Hemoglobinopathies
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
RU2703411C2 (en) 2014-05-01 2019-10-16 Ионис Фармасьютикалз, Инк. Compositions and methods for modulating pkk expression
ES2883837T3 (en) 2014-05-02 2021-12-09 The Res Institute At Nationwide Childrens Hospital Compositions and methods for immunomodulation of anti-LYST
WO2015175539A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Engineering synthetic brain penetrating gene vectors
US10335500B2 (en) 2014-05-12 2019-07-02 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
WO2015184105A1 (en) 2014-05-29 2015-12-03 Trustees Of Dartmouth College Method for selectively inhibiting acat1 in the treatment of neurodegenerative diseases
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN104120127B (en) * 2014-07-01 2016-09-21 清华大学 The oligonucleotide separated and application thereof
AU2015296700B2 (en) 2014-07-29 2021-10-21 Monsanto Technology Llc Compositions and methods for controlling insect pests
WO2016019126A1 (en) 2014-07-30 2016-02-04 The Research Foundation For The State University Of New York System and method for delivering genetic material or protein to cells
US20200230251A1 (en) 2014-08-14 2020-07-23 Friedrich-Schiller-Universitaet Jena Peptide for use in the reduction of side effects in the form of immunostimulatory reactions/effects
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
CN113599539A (en) 2014-08-29 2021-11-05 阿尔尼拉姆医药品有限公司 Methods of Treating Transthyretin (TTR) -mediated amyloidosis
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
WO2016044271A2 (en) 2014-09-15 2016-03-24 Children's Medical Center Corporation Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
EP3197904B1 (en) 2014-09-25 2022-08-10 Cold Spring Harbor Laboratory Treatment of rett syndrome
US11471479B2 (en) 2014-10-01 2022-10-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US20170304459A1 (en) 2014-10-10 2017-10-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
JOP20200115A1 (en) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
CN115040532A (en) 2014-10-10 2022-09-13 伊黛拉制药有限公司 Treatment of cancer using TLR9 agonists and checkpoint inhibitors
US10538762B2 (en) 2014-10-14 2020-01-21 The Board Of Regents Of The University Of Texas System Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAS targeting the expanded hexanucleotide repeat
AU2015336954A1 (en) 2014-10-22 2017-06-08 Katholieke Universiteit Leuven Ku Leuven Research & Development Modulating adipose tissue and adipogenesis
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
UA124449C2 (en) 2014-11-12 2021-09-22 Нмк, Інк. Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
AU2015350120B2 (en) 2014-11-17 2021-05-27 Alnylam Pharmaceuticals, Inc. Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
WO2016081621A1 (en) 2014-11-18 2016-05-26 Yale University Formulations for targeted release of agents under low ph conditions and methods of use thereof
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US20190002876A1 (en) * 2014-12-09 2019-01-03 The Board Of Regents Of The University Of Texas System Compositions and methods for treatment of friedreich's ataxia
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US20180002702A1 (en) * 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
UA124255C2 (en) 2015-01-22 2021-08-18 Монсанто Текнолоджі Елелсі Compositions and methods for controlling leptinotarsa
US10519447B2 (en) 2015-04-01 2019-12-31 Arcturus Therapeutics, Inc. Therapeutic UNA oligomers and uses thereof
EA201792263A1 (en) 2015-04-13 2018-08-31 Элнилэм Фармасьютикалз, Инк. COMPOSITIONS BASED ON iRNA AGAINST ANGIOPOETHIN-LIKE PROTEIN 3 (ANGPTL3) AND METHODS OF THEIR USE
US20180126014A1 (en) 2015-04-15 2018-05-10 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
US10857237B2 (en) 2015-05-05 2020-12-08 University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents
US11572543B2 (en) 2015-05-08 2023-02-07 The Children's Medical Center. Corporation Targeting BCL11A enhancer functional regions for fetal hemoglobin reinduction
CA3026154A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
WO2016201323A1 (en) 2015-06-10 2016-12-15 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
EP3318275A4 (en) * 2015-06-30 2019-02-06 Tadamitsu Kishimoto Novel therapeutic agent for pulmonary disease and/or method for screening same
CN108135923B (en) 2015-07-06 2021-03-02 菲奥医药公司 Nucleic acid molecules targeting superoxide dismutase 1(SOD1)
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
ES2917181T3 (en) 2015-07-10 2022-07-07 Ionis Pharmaceuticals Inc Diacylglycerol acyltransferase 2 (DGAT2) modulators
WO2017015671A1 (en) 2015-07-23 2017-01-26 Arcturus Therapeutics, Inc. Compositions for treating amyloidosis
IL296476A (en) 2015-07-31 2022-11-01 Alnylam Pharmaceuticals Inc Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated diseases
AU2016312530A1 (en) 2015-08-24 2018-03-01 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
MA44908A (en) 2015-09-08 2018-07-18 Sylentis Sau ARNSI MOLECULES AND THEIR USE IN PROCESSES AND COMPOSITIONS TO INHIBIT NRARP GENE EXPRESSION
GB201516685D0 (en) * 2015-09-21 2015-11-04 Varghese Oommen P And Oommen Oommen P Nucleic acid molecules with enhanced activity
US10383935B2 (en) 2015-09-23 2019-08-20 Regents Of The University Of Minnesota Methods of making and using live attenuated viruses
EP3352785A1 (en) 2015-09-23 2018-08-01 Massachusetts Institute Of Technology Compositions and methods for modified dendrimer nanoparticle vaccine delivery
US10086063B2 (en) 2015-09-23 2018-10-02 Regents Of The University Of Minnesota Methods of making and using live attenuated viruses
WO2017058944A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
JOP20210043A1 (en) * 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc Compositions and Methods for Inhibiting Gene Expression of LPA
EP3359555B1 (en) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
JP2018531037A (en) 2015-10-19 2018-10-25 アールエックスアイ ファーマシューティカルズ コーポレーション Reduced size self-delivering nucleic acid compounds targeting long non-coding RNAs
KR20180071362A (en) 2015-11-16 2018-06-27 올릭스 주식회사 Treatment of age-related macular degeneration with RNA complex targeting MyD88 or TLR3
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
ES2844899T3 (en) 2015-12-10 2021-07-23 Fibrogen Inc Methods for treating motor neuron diseases
ES2901102T3 (en) 2015-12-18 2022-03-21 Samyang Holdings Corp Method for preparing a polymeric micelle containing anionic drug
BR102017001164A2 (en) 2016-01-26 2019-03-06 Embrapa - Empresa Brasileira De Pesquisa Agropecuária DOUBLE TAPE RNA COMPOSITIONS FOR CITRI DIAPHORINE CONTROL AND METHODS OF USE.
EP3408391A4 (en) 2016-01-31 2019-08-28 University of Massachusetts Branched oligonucleotides
KR20180104692A (en) 2016-02-02 2018-09-21 올릭스 주식회사 Treatment of angiogenesis related diseases using RNA complexes targeting ANGPT2 and PDGFB
WO2017134525A1 (en) 2016-02-02 2017-08-10 Olix Pharmaceuticals, Inc. TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET lL4Rα, TRPA1, OR F2RL1
US20170360815A1 (en) 2016-02-25 2017-12-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
KR20180120204A (en) 2016-02-25 2018-11-05 어플라이드 바이올로지컬 래버러토리즈 인코포레이티드 Compositions and methods for protecting airborne pathogens and stimulants
AU2017224226A1 (en) 2016-02-26 2018-09-20 Yale University Compositions and methods of using piRNAs in cancer diagnostics and therapeutics
WO2017151623A1 (en) 2016-03-01 2017-09-08 Alexion Pharmaceuticals, Inc. Biodegradable activated polymers for therapeutic delivery
EP3423568A4 (en) 2016-03-04 2019-11-13 University Of Louisville Research Foundation, Inc. Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (vsels)
JP6983797B2 (en) 2016-03-07 2021-12-17 アローヘッド ファーマシューティカルズ インコーポレイテッド Targeted ligand for therapeutic compounds
CA3016474A1 (en) 2016-03-15 2017-09-21 Mersana Therapeutics, Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
MA45470A (en) 2016-04-01 2019-02-06 Avidity Biosciences Llc KRAS NUCLEIC ACIDS AND THEIR USES
MA45328A (en) 2016-04-01 2019-02-06 Avidity Biosciences Llc NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
MA45349A (en) 2016-04-01 2019-02-06 Avidity Biosciences Llc EGFR NUCLEIC ACIDS AND THEIR USES
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
MA45469A (en) 2016-04-01 2019-02-06 Avidity Biosciences Llc BETA-CATENIN NUCLEIC ACIDS AND THEIR USES
DK3440090T3 (en) 2016-04-06 2022-12-19 Ohio State Innovation Foundation RNA-ligand-presenting exosomes for specific delivery of therapeutics to a cell by RNA nanotechnology
CN109072238B (en) 2016-04-11 2022-05-24 奥利克斯医药有限公司 Treatment of idiopathic pulmonary fibrosis using RNA complexes targeting connective tissue growth factor
AU2017250017B2 (en) 2016-04-14 2022-12-22 Benitec IP Holdings Inc. Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
US11410746B2 (en) 2016-04-27 2022-08-09 Massachusetts Institute Of Technology Stable nanoscale nucleic acid assemblies and methods thereof
WO2017197128A1 (en) 2016-05-11 2017-11-16 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
KR101916652B1 (en) 2016-06-29 2018-11-08 올릭스 주식회사 Compounds improving RNA interference of small interfering RNA and use thereof
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
RU2627179C1 (en) * 2016-07-28 2017-08-03 федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Test system for determination of interferon, il23 interleukine and mxa anti-virus protein rna
EP3519582A1 (en) 2016-07-29 2019-08-07 Danmarks Tekniske Universitet Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides
US11123435B2 (en) 2016-08-03 2021-09-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. TLR9 targeted therapeutics
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
CN116942841A (en) 2016-09-02 2023-10-27 箭头药业股份有限公司 Targeting ligands
MX2019002339A (en) 2016-09-02 2019-05-16 Dicerna Pharmaceuticals Inc 4'-phosphate analogs and oligonucleotides comprising the same.
US10933081B2 (en) 2016-09-21 2021-03-02 Alnylam Pharmaceuticals, Inc. Myostatin iRNA compositions and methods of use thereof
JP7129702B2 (en) 2016-09-29 2022-09-02 国立大学法人 東京医科歯科大学 Double-stranded nucleic acid complex with overhangs
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2018107096A1 (en) 2016-12-08 2018-06-14 University Of Utah Research Foundation Staufen1 agents and associated methods
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
KR20190098748A (en) 2017-01-10 2019-08-22 애로우헤드 파마슈티컬스 인코포레이티드 Alpha-1 antitrypsin (AAT) RNAi agent, compositions comprising AAT RNAi agent, and methods of use
WO2018146557A2 (en) 2017-02-10 2018-08-16 Dong Ki Lee Long double-stranded rna for rna interference
DE102017103383A1 (en) 2017-02-20 2018-08-23 aReNA-Bio GbR (vertretungsberechtigter Gesellschafter: Dr. Heribert Bohlen, 50733 Köln) System and method for cell-type specific translation of RNA molecules in eukaryotes
US10934547B2 (en) * 2017-02-20 2021-03-02 Northwestern University Use of trinucleotide repeat RNAs to treat cancer
US20180271996A1 (en) 2017-02-28 2018-09-27 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
WO2018187813A1 (en) 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
CA3060080C (en) 2017-04-14 2024-01-23 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for treating pulmonary fibrosis
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
WO2018218135A1 (en) 2017-05-25 2018-11-29 The Children's Medical Center Corporation Bcl11a guide delivery
US10844377B2 (en) * 2017-06-23 2020-11-24 University Of Massachusetts Two-tailed self-delivering siRNA
AU2018297262A1 (en) 2017-07-06 2020-02-27 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of alpha-ENaC and methods of use
JP7337044B2 (en) 2017-07-13 2023-09-01 アルナイラム ファーマシューティカルズ， インコーポレイテッド Method for inhibiting HAO1 (hydroxy acid oxidase 1 (glycolic acid oxidase)) gene expression
US11104700B2 (en) 2017-07-17 2021-08-31 Oxford University Innovation Limited Oligonucleotides
US11110114B2 (en) 2017-07-17 2021-09-07 Oxford University Innovation Limited Dinucleotides
MX2020002648A (en) 2017-09-11 2020-07-22 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3).
US11806360B2 (en) 2017-09-19 2023-11-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating transthyretin (TTR) mediated amyloidosis
WO2019068326A1 (en) 2017-10-05 2019-04-11 Université D'aix-Marseille Lsd1 inhibitors for the treatment and prevention of cardiomyopathies
RS64001B1 (en) 2017-10-20 2023-03-31 Dicerna Pharmaceuticals Inc Methods for treating hepatitis b infection
US10953036B2 (en) 2017-11-20 2021-03-23 University Of Georgia Research Foundation, Inc. Compositions and methods of modulating HIF-2A to improve muscle generation and repair
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
AU2018375807A1 (en) * 2017-12-01 2020-05-07 The Texas A&M University System Angelman syndrome antisense treatment
EP3720448A4 (en) 2017-12-06 2021-11-03 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
US11597932B2 (en) 2017-12-21 2023-03-07 Alnylam Pharmaceuticals, Inc. Chirally-enriched double-stranded RNA agents
TW201929908A (en) 2017-12-21 2019-08-01 美商梅爾莎納醫療公司 Pyrrolobenzodiazepine antibody conjugates
US10960086B2 (en) 2017-12-28 2021-03-30 Augusta University Research Institute, Inc. Aptamer compositions and methods of use thereof
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
JP2021509669A (en) 2018-01-05 2021-04-01 ディセルナ ファーマシューティカルズ インコーポレイテッド Reduced expression of beta-catenin and IDO to enhance immunotherapy
MX2020007582A (en) 2018-01-16 2020-09-03 Dicerna Pharmaceuticals Inc Compositions and methods for inhibiting aldh2 expression.
PE20211197A1 (en) 2018-02-09 2021-07-01 Genentech Inc OLIGONUCLEOTIDES TO MODULATE THE EXPRESSION OF TMEM106B
EP3790989A1 (en) 2018-05-07 2021-03-17 Roche Innovation Center Copenhagen A/S Massively parallel discovery methods for oligonucleotide therapeutics
EP3791180A1 (en) 2018-05-10 2021-03-17 The University Of Manchester Methods for assessing macular degeneration
EP3807291A4 (en) * 2018-06-14 2022-02-23 University of Utah Research Foundation Staufen1 regulating agents and associated methods
SG11202100715WA (en) 2018-08-13 2021-02-25 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2020051231A1 (en) 2018-09-04 2020-03-12 H. Lee Moffitt Cancer Center & Research Institute Inc. Use of delta-tocotrienol for treating cancer
EP3847650A1 (en) 2018-09-06 2021-07-14 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
EP3873534A1 (en) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
SG11202108532RA (en) 2019-02-12 2021-09-29 Dicerna Pharmaceuticals Inc Methods and compositions for inhibiting expression of cyp27a1
AU2020253823A1 (en) 2019-03-29 2021-10-14 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of KRAS associated diseases or disorders
SG11202110896WA (en) 2019-04-04 2021-10-28 Dicerna Pharmaceuticals Inc Compositions and methods for inhibiting gene expression in the central nervous system
US11814464B2 (en) 2019-04-29 2023-11-14 Yale University Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
AU2020268798A1 (en) 2019-05-03 2021-11-04 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
EP3990028A4 (en) 2019-06-26 2023-08-09 Biorchestra Co., Ltd. Micellar nanoparticles and uses thereof
KR20220101073A (en) 2019-08-30 2022-07-19 예일 유니버시티 Compositions and methods for delivering nucleic acids into cells
AU2020345317A1 (en) 2019-09-10 2022-04-21 Daiichi Sankyo Company, Limited CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF
MX2022004032A (en) 2019-10-02 2022-09-21 Dicerna Pharmaceuticals Inc Chemical modifications of small interfering rna with minimal fluorine content.
US11355185B2 (en) 2019-11-26 2022-06-07 Cypress Semiconductor Corporation Silicon-oxide-nitride-oxide-silicon multi-level non-volatile memory device and methods of fabrication thereof
JP2023509872A (en) 2019-12-24 2023-03-10 エフ． ホフマン－ラ ロシュ アーゲー Pharmaceutical combinations of antiviral agents targeting HBV and/or immunomodulatory agents for the treatment of HBV
EP4081639A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
KR20220141299A (en) 2020-01-14 2022-10-19 신테카인, 인크. IL2 Orthologs and Instructions for Use
US20210222128A1 (en) 2020-01-22 2021-07-22 Massachusetts Institute Of Technology Inducible tissue constructs and uses thereof
WO2021173965A1 (en) 2020-02-28 2021-09-02 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
US20230287425A1 (en) 2020-03-18 2023-09-14 Dicerna Pharmacuticals Inc. Compositions and methods for inhibiting angptl3 expression
CN115666589A (en) 2020-03-19 2023-01-31 艾维迪提生物科学公司 Compositions and methods for treating facioscapulohumeral muscular dystrophy
CN115697418A (en) 2020-03-27 2023-02-03 艾维迪提生物科学公司 Compositions and methods for treating muscular dystrophy
AU2021258257A1 (en) 2020-04-22 2022-11-10 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
BR112022025855A2 (en) 2020-06-19 2023-01-10 Univ Yale POLYMER, METHOD OF ADMINISTRATION OF ONE OR MORE THERAPEUTIC, DIAGNOSTIC OR PROPHYLACTIC NUCLEIC ACID AGENTS, OR COMBINATIONS THEREOF IN VIVO
WO2021255262A1 (en) 2020-06-19 2021-12-23 Sylentis Sau siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
US20220031633A1 (en) 2020-07-28 2022-02-03 Yale University Poly(amine-co-ester) polymeric particles for selective pulmonary delivery
IL300286A (en) 2020-08-04 2023-04-01 Dicerna Pharmaceuticals Inc Compositions and methods for inhibiting plp1 expression
CA3187220A1 (en) 2020-08-04 2022-02-10 Dicerna Pharmaceuticals, Inc. Systemic delivery of oligonucleotides
TW202221120A (en) 2020-08-04 2022-06-01 美商黛瑟納製藥公司 Compositions and methods for the treatment of metabolic syndrome
MX2023001443A (en) 2020-08-05 2023-04-14 Hoffmann La Roche Oligonucleotide treatment of hepatitis b patients.
BR112023001957A2 (en) 2020-08-05 2023-04-25 Dicerna Pharmaceuticals Inc COMPOSITIONS AND METHODS TO INHIBIT LPA EXPRESSION
US20230265214A1 (en) 2020-08-31 2023-08-24 Yale University Compositions and methods for delivery of nucleic acids to cells
EP3964204A1 (en) 2020-09-08 2022-03-09 Université d'Aix-Marseille Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
WO2022058447A1 (en) 2020-09-16 2022-03-24 The University Of Manchester Complementome assay
IL303195A (en) 2020-11-25 2023-07-01 Akagera Medicines Inc Lipid nanoparticles for delivery of nucleic acids, and related methods of use
CN117295753A (en) 2020-12-04 2023-12-26 基那奥生物公司 Compositions and methods for delivering nucleic acids to cells
EP4015634A1 (en) 2020-12-15 2022-06-22 Sylentis, S.A.U. Sirna and compositions for prophylactic and therapeutic treatment of virus diseases
CA3212128A1 (en) 2021-03-04 2022-09-09 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
JP2024511839A (en) 2021-03-31 2024-03-15 カーマイン・セラピューティクス・プライベート・リミテッド Extracellular vesicles carrying at least two different nucleic acids
KR20230170732A (en) 2021-04-12 2023-12-19 베링거 인겔하임 인터내셔날 게엠베하 Compositions and methods for inhibiting ketohexokinase (KHK)
CN117120613A (en) 2021-04-14 2023-11-24 迪克纳制药公司 Compositions and methods for modulating PNPLA3 expression
TW202305136A (en) 2021-04-19 2023-02-01 美商戴瑟納製藥股份有限公司 Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
IL308418A (en) 2021-05-28 2024-01-01 Novo Nordisk As Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (marc1) expression
KR20240014533A (en) 2021-05-29 2024-02-01 1글로브 헬스 인스티튜트 엘엘씨 Short duplex DNA and its uses as a novel gene silencing technology
EP4347829A1 (en) 2021-05-29 2024-04-10 1Globe Health Institute LLC Asymmetric short duplex dna as a novel gene silencing technology and use thereof
CA3174095A1 (en) 2021-06-23 2022-12-29 Vignesh Narayan HARIHARAN Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
WO2023014677A1 (en) 2021-08-03 2023-02-09 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof
WO2023021046A1 (en) 2021-08-16 2023-02-23 Vib Vzw Oligonucleotides for modulating synaptogyrin-3 expression
US20230107967A1 (en) 2021-08-25 2023-04-06 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting alpha-1 antitrypsin expression
CA3232054A1 (en) 2021-09-21 2023-03-30 Kannan Rangaramanujam Dendrimer conjugates of small molecule biologics for intracellular delivery
WO2023083906A2 (en) 2021-11-11 2023-05-19 F. Hoffmann-La Roche Ag Pharmaceutical combinations for treatment of hbv
EP4340893A1 (en) 2021-11-19 2024-03-27 KIST (Korea Institute of Science and Technology) Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell
WO2023102469A2 (en) 2021-12-01 2023-06-08 Dicerna Pharmaceuticals, Inc. Compositions and methods for modulating apoc3 expression
WO2023118546A2 (en) 2021-12-23 2023-06-29 Boehringer Ingelheim International Gmbh METHODS AND MOLECULES FOR RNA INTERFERENCE (RNAi)
WO2023159189A1 (en) 2022-02-18 2023-08-24 Yale University Branched poly(amine-co-ester) polymers for more efficient nucleic expression
GB202203627D0 (en) 2022-03-16 2022-04-27 Univ Manchester Agents for treating complement-related disorders
US20230302423A1 (en) 2022-03-28 2023-09-28 Massachusetts Institute Of Technology Rna scaffolded wireframe origami and methods thereof
GB202204884D0 (en) 2022-04-04 2022-05-18 Fondo Ricerca Medica S R I Sirna targeting kcna1
TW202345873A (en) 2022-04-15 2023-12-01 美商戴瑟納製藥股份有限公司 Compositions and methods for modulatingscapactivity
US20230416742A1 (en) 2022-05-12 2023-12-28 Dicerna Phrmaceuticals, Inc. Compositions and methods for inhibiting mapt expression
US20230416743A1 (en) 2022-05-13 2023-12-28 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting snca expression
TW202400193A (en) 2022-06-24 2024-01-01 丹麥商諾佛 儂迪克股份有限公司 Compositions and methods for inhibiting transmembrane serine protease 6 (tmprss6) expression
WO2024040041A1 (en) 2022-08-15 2024-02-22 Dicerna Pharmaceuticals, Inc. Regulation of activity of rnai molecules
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075164A2 (en) * 2000-03-30 2001-10-11 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003006A (en) * 1933-04-11 1935-05-28 Michelson Barnett Samuel Water tank cover
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5208149A (en) * 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
GB8704365D0 (en) * 1987-02-25 1987-04-01 Exxon Chemical Patents Inc Zeolite l preparation
US5712257A (en) * 1987-08-12 1998-01-27 Hem Research, Inc. Topically active compositions of mismatched dsRNAs
IE66830B1 (en) 1987-08-12 1996-02-07 Hem Res Inc Topically active compositions of double-stranded RNAs
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0942000B1 (en) * 1989-10-24 2004-06-23 Isis Pharmaceuticals, Inc. 2'-Modified oligonucleotides
US5457189A (en) * 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
ATE271064T1 (en) 1990-01-11 2004-07-15 Isis Pharmaceuticals Inc OLIGONUCLEOTIDE DERIVATIVES FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION
US5670633A (en) * 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5514577A (en) * 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
CA2093664C (en) * 1990-10-12 2003-07-29 Fritz Eckstein Modified ribozymes
FR2675803B1 (en) 1991-04-25 1996-09-06 Genset Sa CLOSED, ANTISENSE AND SENSE OLIGONUCLEOTIDES AND THEIR APPLICATIONS.
WO1994008003A1 (en) * 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
FR2685346B1 (en) * 1991-12-18 1994-02-11 Cis Bio International PROCESS FOR THE PREPARATION OF DOUBLE-STRANDED RNA, AND ITS APPLICATIONS.
EP0635023B1 (en) * 1992-03-05 2002-02-06 Isis Pharmaceuticals, Inc. Covalently cross-linked oligonucleotides
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
US20030171311A1 (en) * 1998-04-27 2003-09-11 Lawrence Blatt Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
WO2002081494A1 (en) * 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US20030068301A1 (en) * 1992-05-14 2003-04-10 Kenneth Draper Method and reagent for inhibiting hepatitis B virus replication
US20040054156A1 (en) * 1992-05-14 2004-03-18 Kenneth Draper Method and reagent for inhibiting hepatitis B viral replication
HUT69981A (en) 1992-07-02 1995-09-28 Hybridon Inc Self-stabilized oligonucleotides as therapeutic agents
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
WO1994015645A1 (en) 1992-12-31 1994-07-21 Texas Biotechnology Corporation Antisense molecules directed against genes of the raf oncogene family
US6056704A (en) * 1993-03-03 2000-05-02 Ide; Masatake Foot-pressure massage stand
EP0616026A1 (en) 1993-03-19 1994-09-21 The Procter & Gamble Company Concentrated cleaning compositions
WO1995000638A2 (en) * 1993-06-23 1995-01-05 Genesys Pharma Inc. Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
FR2710074B1 (en) 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa GRB3-3 gene, its variants and their uses.
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
NZ277617A (en) 1993-11-16 1998-01-26 Genta Inc Chimeric oligonucleoside compounds useful in activating rnaseh mediated cleavage of ribonucleic acid sequences
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5908779A (en) * 1993-12-01 1999-06-01 University Of Connecticut Targeted RNA degradation using nuclear antisense RNA
JPH10503364A (en) * 1994-05-10 1998-03-31 ザ ジェネラル ホスピタル コーポレーション Antisense inhibition of hepatitis C virus
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US5674683A (en) * 1995-03-21 1997-10-07 Research Corporation Technologies, Inc. Stem-loop and circular oligonucleotides and method of using
US5624808A (en) * 1995-03-28 1997-04-29 Becton Dickinson And Company Method for identifying cells committed to apoptosis by determining cellular phosphotyrosine content
JP4335310B2 (en) 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア Lipid-nucleic acid particles prepared through hydrophobic lipid-nucleic acid complex intermediates and use for gene transfer
EP0851919A1 (en) * 1995-09-20 1998-07-08 University of Massachusetts Worcester Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
JP4293636B2 (en) 1996-02-14 2009-07-08 アイシス・ファーマシューティカルス・インコーポレーテッド Oligonucleotide with sugar-modified gap
CA2251945A1 (en) 1996-04-17 1997-10-23 Aronex Pharmaceuticals, Inc. Antisense inhibitors of vascular endothelial growth factor (vefg/vpf) expression
DE19618797C2 (en) 1996-05-10 2000-03-23 Bertling Wolf Vehicle for the transport of molecular substances
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20040266706A1 (en) 2002-11-05 2004-12-30 Muthiah Manoharan Cross-linked oligomeric compounds and their use in gene modulation
DE19631919C2 (en) 1996-08-07 1998-07-16 Deutsches Krebsforsch Anti-sense RNA with secondary structure
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
ATE329015T1 (en) * 1996-10-04 2006-06-15 Derek Nigel John Hart ENZYMES WITH S-ADENOSYL-L-HOMOCYSTEIN HYDROLASE-LIKE ACTIVITY.
US5814500A (en) * 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
ATE352614T1 (en) 1996-12-12 2007-02-15 Yissum Res Dev Co SYNTHETIC ANTISENSE OLIGODEOXYNUCLEOTIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US20030064945A1 (en) * 1997-01-31 2003-04-03 Saghir Akhtar Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
GB9703146D0 (en) * 1997-02-14 1997-04-02 Innes John Centre Innov Ltd Methods and means for gene silencing in transgenic plants
US6218142B1 (en) * 1997-03-05 2001-04-17 Michael Wassenegger Nucleic acid molecules encoding polypeptides having the enzymatic activity of an RNA-directed RNA polymerase (RDRP)
GB9710475D0 (en) 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
CA2303299C (en) 1997-09-12 2016-02-23 Exiqon A/S Oligonucleotide analogues
JP2002508299A (en) 1997-09-19 2002-03-19 セクイター， インク． Sense mRNA therapy
GB9720148D0 (en) 1997-09-22 1997-11-26 Innes John Centre Innov Ltd Gene silencing materials and methods
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6475726B1 (en) * 1998-01-09 2002-11-05 Cubist Pharmaceuticals, Inc. Method for identifying validated target and assay combinations for drug development
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP1071762A4 (en) 1998-03-20 2003-09-24 Benitec Australia Ltd Control of gene expression
US20040214330A1 (en) * 1999-04-07 2004-10-28 Waterhouse Peter Michael Methods and means for obtaining modified phenotypes
EP1068311B2 (en) 1998-04-08 2020-12-09 Commonwealth Scientific and Industrial Research Organisation Methods and means for obtaining modified phenotypes
EP1071753A2 (en) 1998-04-20 2001-01-31 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
AR020078A1 (en) 1998-05-26 2002-04-10 Syngenta Participations Ag METHOD FOR CHANGING THE EXPRESSION OF AN OBJECTIVE GENE IN A PLANT CELL
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
WO2000031271A1 (en) 1998-11-24 2000-06-02 Hisamitsu Pharmaceutical Co., Inc. Hiv infection inhibitors
AU1830000A (en) 1998-11-30 2000-06-19 Ribogene, Inc. Methods and compositions for identification of inhibitors of ribosome assembly
US6939712B1 (en) * 1998-12-29 2005-09-06 Impedagen, Llc Muting gene activity using a transgenic nucleic acid
CA2361201A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (en) * 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
JP2002542263A (en) 1999-04-21 2002-12-10 ワイス Methods and compositions for inhibiting the function of a polynucleotide sequence
US20040002153A1 (en) * 1999-07-21 2004-01-01 Monia Brett P. Modulation of PTEN expression via oligomeric compounds
GB9925459D0 (en) * 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (en) 2001-01-09 2002-04-11 Ribopharma Ag Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
DE10160151A1 (en) 2001-01-09 2003-06-26 Ribopharma Ag Inhibiting expression of target gene, useful e.g. for inhibiting oncogenes, by administering double-stranded RNA complementary to the target and having an overhang
RU2164944C1 (en) * 1999-12-09 2001-04-10 Институт молекулярной биологии им. В.А. Энгельгардта РАН Method of alternation of organism genetic features
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
AU2001260114A1 (en) 2000-03-14 2001-09-24 Syngenta Participations Ag Protoporphyrinogen oxidase ("protox") genes
IL151781A0 (en) * 2000-03-16 2003-04-10 Genetica Inc Methods and compositions for rna interference
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
BRPI0117338B1 (en) 2000-03-30 2016-06-21 Massachusetts Inst Technology method for producing knockout animal cells in vitro and method for producing knockout animal cells
WO2001092513A1 (en) 2000-05-30 2001-12-06 Johnson & Johnson Research Pty Limited METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi
CZ308053B6 (en) * 2000-12-01 2019-11-27 Max Planck Gesellschaft Isolated double-stranded RNA molecule, process for producing it and its use
WO2002061034A2 (en) 2000-12-08 2002-08-08 Invitrogen Corporation Compositions and methods for rapidly generating recombinant nucleic acid molecules
JP2004532616A (en) * 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド Double-stranded RNA-mediated gene suppression
WO2003035869A1 (en) 2001-10-26 2003-05-01 Ribopharma Ag Use of a double-stranded ribonucleic acid for specifically inhibiting the expression of a given target gene
US7423142B2 (en) * 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
CA2369944A1 (en) * 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US20040006035A1 (en) * 2001-05-29 2004-01-08 Dennis Macejak Nucleic acid mediated disruption of HIV fusogenic peptide interactions
US20040019001A1 (en) * 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
EP1390472A4 (en) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
DE50101770D1 (en) 2001-06-01 2004-04-29 Mobilkom Austria Ag & Co Kg Wi Method for determining the location of a mobile station in a mobile radio system
US20030140362A1 (en) * 2001-06-08 2003-07-24 Dennis Macejak In vivo models for screening inhibitors of hepatitis B virus
WO2003029459A2 (en) 2001-09-28 2003-04-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Micro-rna molecules
DE10163098B4 (en) 2001-10-12 2005-06-02 Alnylam Europe Ag Method for inhibiting the replication of viruses
US20040121348A1 (en) * 2001-10-26 2004-06-24 Ribopharma Ag Compositions and methods for treating pancreatic cancer
CN1608133A (en) * 2001-10-26 2005-04-20 里伯药品公司 Use of a double-stranded ribonucleic acid for treating an infection with a positivestrand rna-virus
DE10230997A1 (en) * 2001-10-26 2003-07-17 Ribopharma Ag Drug to increase the effectiveness of a receptor-mediates apoptosis in drug that triggers tumor cells
DE10154113A1 (en) 2001-11-03 2003-05-15 Opel Adam Ag Front structure of a motor vehicle
DE10202419A1 (en) * 2002-01-22 2003-08-07 Ribopharma Ag Method of inhibiting expression of a target gene resulting from chromosome aberration
EP1572902B1 (en) 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
WO2003068797A1 (en) * 2002-02-14 2003-08-21 City Of Hope Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules
AU2003228301A1 (en) * 2002-03-06 2003-09-22 Rigel Pharmaceuticals, Inc. Novel method for delivery and intracellular synthesis of sirna molecules
EP1495141A4 (en) * 2002-03-20 2006-03-22 Massachusetts Inst Technology Hiv therapeutic
US20030180756A1 (en) * 2002-03-21 2003-09-25 Yang Shi Compositions and methods for suppressing eukaryotic gene expression
US20040053876A1 (en) * 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof
AU2003237686A1 (en) 2002-05-24 2003-12-12 Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Rna interference mediating small rna molecules
AU2003273995A1 (en) 2002-06-05 2003-12-22 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
GB2406169B (en) 2002-06-12 2006-11-01 Ambion Inc Methods and compositions relating to labeled rna molecules that reduce gene expression
EP2333062A1 (en) 2002-07-10 2011-06-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA-interference by single-stranded RNA molecules
DE60310944T3 (en) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh OTHER NEW FORMS OF INTERFERING RNS MOLECULES
US20040241854A1 (en) * 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
AU2003261449A1 (en) * 2002-08-07 2004-02-25 Compositions for rna interference and methods of use thereof
AU2003273336A1 (en) 2002-09-18 2004-04-08 Isis Pharmaceuticals, Inc. Efficient reduction of target rna's by single- and double-stranded oligomeric compounds
CA2500224C (en) 2002-09-25 2015-04-28 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
EP1578765A4 (en) 2002-11-05 2008-04-23 Isis Pharmaceuticals Inc Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
JP2006507841A (en) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド Functional and ultrafunctional siRNA
WO2004046324A2 (en) 2002-11-15 2004-06-03 University Of Massachusetts Allele-targeted rna interference
AU2003298718A1 (en) * 2002-11-22 2004-06-18 University Of Massachusetts Modulation of hiv replication by rna interference
WO2004063375A1 (en) 2003-01-15 2004-07-29 Hans Prydz OPTIMIZING siRNA BY RNAi ANTISENSE
US20040224328A1 (en) * 2003-01-15 2004-11-11 Hans Prydz siRNA screening method
EP2314687B1 (en) 2003-01-17 2017-12-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inducible small interfering rna (sirna) expression constructs for targeted gene silencing
WO2004065600A2 (en) 2003-01-17 2004-08-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference by palindromic or modified rna molecules
AU2004215097A1 (en) 2003-02-10 2004-09-10 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by DNA interference
WO2004073390A1 (en) * 2003-02-19 2004-09-02 Commonwealth Scientific And Industrial Research Organisation Efficient gene silencing in plants using short dsrna sequences
EP1633767B1 (en) 2003-06-02 2018-11-21 University of Massachusetts Methods and compositions for controlling efficacy of rna silencing
US6998203B2 (en) * 2003-08-01 2006-02-14 Intel Corporation Proximity correcting lithography mask blanks
NZ556097A (en) * 2005-01-07 2009-12-24 Alnylam Pharmaceuticals Inc Rnai modulation of RSV and therapeutic uses thereof
WO2013009634A2 (en) 2011-07-08 2013-01-17 Inteva Products Llc. Method for stitching vehicle interior components and components formed from the method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075164A2 (en) * 2000-03-30 2001-10-11 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BASS BRENDA L: "Double-stranded RNA as a template for gene silencing.", CELL, vol. 101, no. 3, 28 April 2000 (2000-04-28), pages 235 - 238, XP002194756, ISSN: 0092-8674 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992, VINAYAK R ET AL: "CHEMICAL SYNTHESIS OF RNA USING FAST OLIGONUCLEOTIDE DEPROTECTION CHEMISTRY", XP002247596, Database accession no. PREV199294000583 *
ELBASHIR SAYDA M ET AL: "RNA interference is mediated by 21- and 22-nucleotide RNAs", GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, NEW YORK, US, vol. 15, no. 2, 15 January 2001 (2001-01-15), pages 188 - 200, XP002204651, ISSN: 0890-9369 *
HAMILTON ANDREW J ET AL: "A species of small antisense RNA in posttranscriptional gene silencing in plants", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 286, no. 5441, 29 October 1999 (1999-10-29), pages 950 - 952, XP002149064, ISSN: 0036-8075 *
HAMMOND SCOTT M ET AL: "An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 404, no. 6775, 16 March 2000 (2000-03-16), pages 293 - 296, XP002183123, ISSN: 0028-0836 *
NUCLEIC ACIDS RESEARCH, vol. 20, no. 6, 1992, pages 1265 - 1269, ISSN: 0305-1048 *
TUSCHL THOMAS ET AL: "Targeted mRNA degradation by double-stranded RNA in vitro", GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, NEW YORK, US, vol. 13, no. 24, 15 December 1999 (1999-12-15), pages 3191 - 3197, XP002183118, ISSN: 0890-9369 *
YANG DUN ET AL: "Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi in Drosophila embryos.", CURRENT BIOLOGY, vol. 10, no. 19, 19 September 2000 (2000-09-19), pages 1191 - 1200, XP001037751, ISSN: 0960-9822 *
ZAMORE PHILLIP D ET AL: "RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 101, no. 1, 31 March 2000 (2000-03-31), pages 25 - 33, XP002208683, ISSN: 0092-8674 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7888325B2 (en) 1999-01-28 2011-02-15 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US8148345B2 (en) 1999-01-28 2012-04-03 Georgia Health Sciences University Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US8895266B2 (en) 2000-10-06 2014-11-25 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell
US9409982B2 (en) 2000-10-06 2016-08-09 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell
US9051566B2 (en) 2001-01-31 2015-06-09 Alnylam Pharmaceuticals, Inc. Post-transcriptional gene silencing using expressed double stranded RNA
US9592250B2 (en) 2002-02-01 2017-03-14 Life Technologies Corporation Double-stranded oligonucleotides
US8846894B2 (en) 2002-02-20 2014-09-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7655232B2 (en) 2002-12-24 2010-02-02 Pfizer Inc. Anti-NGF antibodies and methods using same
US9447414B2 (en) 2004-11-12 2016-09-20 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US9506061B2 (en) 2004-11-12 2016-11-29 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US8946177B2 (en) 2004-11-12 2015-02-03 Mima Therapeutics, Inc Methods and compositions involving miRNA and miRNA inhibitor molecules
US8999947B2 (en) 2005-06-14 2015-04-07 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US9506056B2 (en) 2006-06-08 2016-11-29 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US9279009B2 (en) 2007-12-03 2016-03-08 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services FILIP1L nucleic acid fragments
US9376690B2 (en) 2009-10-30 2016-06-28 Northwestern University Templated nanoconjugates
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor

Also Published As

Publication number Publication date
CA2429814A1 (en) 2002-06-06
DK1407044T3 (en) 2008-01-28
US8445237B2 (en) 2013-05-21
US20040259248A1 (en) 2004-12-23
US20100316703A1 (en) 2010-12-16
CZ20031839A3 (en) 2003-10-15
US8895721B2 (en) 2014-11-25
IL155991A (en) 2013-06-27
HUP0302557A3 (en) 2005-12-28
US20110027883A1 (en) 2011-02-03
ES2215494T3 (en) 2008-04-01
US20170327822A1 (en) 2017-11-16
US20200299693A1 (en) 2020-09-24
AU3574402A (en) 2002-06-11
CN1568373A (en) 2005-01-19
AU2010212438B2 (en) 2013-05-09
DK2813582T3 (en) 2017-07-31
EP2348133A1 (en) 2011-07-27
KR20080069602A (en) 2008-07-28
WO2002044321A2 (en) 2002-06-06
ATE373724T2 (en) 2007-10-15
NO333713B1 (en) 2013-09-02
SI1407044T1 (en) 2008-04-30
US20070093445A1 (en) 2007-04-26
CN100523215C (en) 2009-08-05
HK1139433A1 (en) 2010-09-17
DK1407044T4 (en) 2017-12-04
EP1407044B1 (en) 2007-09-19
AU2010212438A1 (en) 2010-09-09
BRPI0115814B8 (en) 2021-05-25
CY1119062T1 (en) 2018-01-10
US20080269147A1 (en) 2008-10-30
CZ2011452A3 (en) 2003-10-15
AU2007203385B2 (en) 2010-05-20
AU2010212438A2 (en) 2010-09-23
KR100872437B1 (en) 2008-12-05
US20040259247A1 (en) 2004-12-23
EP2348133B1 (en) 2014-07-16
US8778902B2 (en) 2014-07-15
NZ525888A (en) 2006-04-28
US8329463B2 (en) 2012-12-11
DE60130583D1 (en) 2007-10-31
US9567582B2 (en) 2017-02-14
HK1204798A1 (en) 2015-12-04
JP4095895B2 (en) 2008-06-04
US20040229266A1 (en) 2004-11-18
US20110065109A1 (en) 2011-03-17
US8362231B2 (en) 2013-01-29
EP1873259B1 (en) 2012-01-25
US20110065773A1 (en) 2011-03-17
US20110070162A1 (en) 2011-03-24
ES2215494T5 (en) 2017-12-28
TR200401292T3 (en) 2004-07-21
IL207727A (en) 2014-04-30
BRPI0115814B1 (en) 2019-10-15
RU2470073C2 (en) 2012-12-20
LTPA2021005I1 (en) 2021-06-10
IL155991A0 (en) 2003-12-23
US8933044B2 (en) 2015-01-13
US8372968B2 (en) 2013-02-12
US8993745B2 (en) 2015-03-31
HUP0302557A2 (en) 2003-10-28
DE60130583T3 (en) 2018-03-22
PL218876B1 (en) 2015-02-27
US7078196B2 (en) 2006-07-18
US20110014123A1 (en) 2011-01-20
JP2015061534A (en) 2015-04-02
US8895718B2 (en) 2014-11-25
MXPA03004836A (en) 2005-09-08
US20110054159A1 (en) 2011-03-03
NO20032464L (en) 2003-07-21
US20050234007A1 (en) 2005-10-20
KR100909681B1 (en) 2009-07-29
US20050026278A1 (en) 2005-02-03
JP2010131031A (en) 2010-06-17
JP2004526422A (en) 2004-09-02
KR20040012686A (en) 2004-02-11
PL365784A1 (en) 2005-01-10
US20110306651A1 (en) 2011-12-15
EP1873259A1 (en) 2008-01-02
US10633656B2 (en) 2020-04-28
US8853384B2 (en) 2014-10-07
EP1407044A2 (en) 2004-04-14
AU2002235744B8 (en) 2007-06-28
JP5749892B2 (en) 2015-07-15
HK1110631A1 (en) 2008-07-18
US20130125259A1 (en) 2013-05-16
RU2322500C2 (en) 2008-04-20
JP2007111053A (en) 2007-05-10
NO20032464D0 (en) 2003-05-30
NO20130246L (en) 2003-07-21
RU2007131270A (en) 2009-02-27
ZA200303929B (en) 2004-07-19
CA2429814C (en) 2014-02-18
US7056704B2 (en) 2006-06-06
HK1139181A1 (en) 2010-09-10
PT1407044E (en) 2008-01-02
US20110112283A1 (en) 2011-05-12
JP4494392B2 (en) 2010-06-30
ES2728168T3 (en) 2019-10-22
HU230458B1 (en) 2016-07-28
JP6325974B2 (en) 2018-05-16
EP1407044B2 (en) 2017-11-15
CZ308053B6 (en) 2019-11-27
BR0115814A (en) 2004-03-23
NO335426B1 (en) 2014-12-15
US20100292456A1 (en) 2010-11-18
US20090155174A1 (en) 2009-06-18
AU2002235744B2 (en) 2007-04-19
DE60130583T2 (en) 2008-06-12
US8765930B2 (en) 2014-07-01
US20110020234A1 (en) 2011-01-27
ES2215494T1 (en) 2004-10-16
JP2009284915A (en) 2009-12-10
CZ302719B6 (en) 2011-09-21
US20100010207A1 (en) 2010-01-14
SI1407044T2 (en) 2018-03-30
US20050234006A1 (en) 2005-10-20
US20150141492A1 (en) 2015-05-21
AU2007203385A1 (en) 2007-08-09
JP6189576B2 (en) 2017-08-30
US8796016B2 (en) 2014-08-05

Similar Documents

Publication Publication Date Title
LTPA2021005I1 (en)
SI2813582T1 (en) RNA interference mediating small RNA molecules
CY1114955T1 (en) SMALL RNAs Molecules That Cause RNA Interference

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
EL Fr: translation of claims filed
WWE Wipo information: entry into national phase

Ref document number: 612/KOLNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 525888

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002235744

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 155991

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200303929

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2429814

Country of ref document: CA

Ref document number: 1020037006978

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002546670

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/004836

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 018209009

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001985833

Country of ref document: EP

ENP Entry into the national phase

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: PV2003-1839

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-1839

Country of ref document: CZ

TCAT At: translation of claims filed
WWP Wipo information: published in national office

Ref document number: 1020037006978

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001985833

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10433050

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002235744

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2001985833

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 207727

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2011-452

Country of ref document: CZ